Identification of Intracranial Lesions with Dual-Energy Computed Tomography and Magnetic Resonance Phase Imaging by Jacobsen, Megan C
Texas Medical Center Library
DigitalCommons@TMC
UT GSBS Dissertations and Theses (Open Access) Graduate School of Biomedical Sciences
8-2018
Identification of Intracranial Lesions with Dual-
Energy Computed Tomography and Magnetic
Resonance Phase Imaging
Megan C. Jacobsen
Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Medicine and Health Sciences Commons, and the Other Physics Commons
This Dissertation (PhD) is brought to you for free and open access by the
Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has
been accepted for inclusion in UT GSBS Dissertations and Theses (Open
Access) by an authorized administrator of DigitalCommons@TMC. For
more information, please contact laurel.sanders@library.tmc.edu.
Recommended Citation
Jacobsen, Megan C., "Identification of Intracranial Lesions with Dual-Energy Computed Tomography and Magnetic Resonance Phase
Imaging" (2018). UT GSBS Dissertations and Theses (Open Access). 881.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/881
 i 
 
IDENTIFICATION OF INTRACRANIAL LESIONS WITH DUAL-ENERGY COMPUTED 
TOMOGRAPHY AND MAGNETIC RESONANCE PHASE IMAGING 
by 
Megan C. Jacobsen, B.A. 
APPROVED:  
 
 
 
____________________________________ 
Dianna Cody, Ph.D. 
Advisory Professor 
 
 
 
____________________________________ 
Dawid Schellingerhout, M.D. 
Secondary Mentor 
 
 
____________________________________ 
Ken-Pin Hwang, Ph.D. 
 
 
 
____________________________________ 
Lucia LeRoux, Ph.D. 
 
 
 
____________________________________ 
Xinming Liu, Ph.D. 
 
 
 
____________________________________ 
Veera Baladandayuthapani, Ph.D. 
Approval Page 
APPROVED: 
 
 
 
____________________________ 
Dean, The University of Texas MD Anderson Cancer Center UTHealth  
Graduate School of Biomedical Sciences 
 ii 
 
 
IDENTIFICATION OF INTRACRANIAL LESIONS WITH DUAL-ENERGY COMPUTED 
TOMOGRAPHY AND MAGNETIC RESONANCE PHASE IMAGING 
 
A 
DISSERTATION 
Presented to the Faculty of  
 
The University of Texas MD Anderson Cancer Center UTHealth  
Graduate School of Biomedical Sciences  
 
in Partial Fulfillment 
of the Requirements 
for the Degree of 
 
DOCTOR OF PHILOSOPHY 
 
 
by 
Megan C. Jacobsen, B.A. 
Houston, Texas 
August 2018 
Title Page 
 
 iii 
 
Acknowledgements 
 
This work would not have been possible without the guidance of my advisors, Dianna 
Cody and Dawid Schellingerhout. They have spent a significant amount of time and 
effort guiding my research over the past six years and have been there to impart their 
knowledge to me through the highs and lows of research. I would also like to thank the 
rest of my advisory committee for their input throughout my doctoral research. Ken-Pin 
Hwang has attended nearly every lab meeting since we began developing our trial and 
has painstakingly guided me through the world of MRI for several years without 
complaint. Lucia Le Roux has served as a personal mentor who has always taken the 
time to talk with me about life, agarose gel phantoms, and managed to teach this 
laboratory-deficient physicist how to use a pipette. I would like to thank Xinming Liu for 
supporting various CT projects throughout the course of my doctoral work, and Veera 
Baladandayuthapani for providing input on statistical matters great and small. Thank 
you all for serving on my committee for the past five years. 
I would like to thank all of the additional MD Anderson staff that have made this 
research feasible, including Kathy Prentice, the staff of the Center for Advanced 
Biomedical Imaging, the Medical Imaging Technologist team, and the research nurses 
from Diagnostic Imaging. Michelle, Riya, Cynthia, and Jerica have contacted every one 
of our patients and met with them one-on-one. Wolfgang Stefan developed fantastic 
software to enable myself and Dr. Schellingerhout to easily screen patients. 
 
 iv 
 
Finally, I would like to thank my support network both at home and at work. My partner, 
Justin Chen, has been with me through thick and thin for over five years. My parents 
and sisters have supported this venture from day one. Jessica Nute, my former lab 
mate, taught me how to use a CT scanner, guided me through the early years of my 
PhD, and has been an amazing friend and mentor. I would also like to acknowledge my 
former officemates, Chris MacLellan and Sam Fahrenholtz, for their comradery. Finally, 
thank you to Cayla Wood and Molly McCulloch for both their companionship and for 
helping to determine that the optimal number of references for this dissertation must 
end in the number 9. 
 
  
 v 
 
IDENTIFICATION OF INTRACRANIAL LESIONS WITH DUAL-ENERGY COMPUTED 
TOMOGRAPHY AND MAGNETIC RESONANCE PHASE IMAGING 
 
Megan C. Jacobsen, B.A. 
Advisory Professors: Dianna Cody, Ph.D. & Dawid Schellingerhout, M.D. 
Abstract 
On conventional Single-energy Computed Tomography (SECT), lesions with an 
attenuation greater than 100 Hounsfield Units (HU) can be definitively diagnosed as 
calcification. However, low-density calcifications and hemorrhage may have overlapping 
attenuation ranges between 40 and 100 HU and, therefore, cannot be differentiated with SECT 
alone. On T2*-weighted Gradient Recalled Echo (GRE) MRI, these lesions appear as “foci of 
susceptibility” in which their signal is hypointense due to the magnetic susceptibility of the 
lesions differing from that of the background tissue.  
Dual-energy Computed Tomography (DECT) and Phase-Sensitive Magnetic 
Resonance Imaging (PS-MRI) represent two new imaging paradigms which both have the 
potential to more accurately identify intracranial calcification and hemorrhage. In DECT, x-ray 
tomography is acquired at two tube voltages; because x-ray attenuation is energy- and 
material-dependent, the data can be used to differentiate between materials that may have the 
same signal level on SECT. PS-MRI utilizes the phase data from T2*-weighted MRI 
acquisitions to determine how the local magnetic field varies across the image. By applying 
post-processing algorithms such as Quantitative Susceptibility Mapping (QSM), the phase can 
be used to calculate the magnetic susceptibility of a lesion. Since calcifications are diamagnetic 
and hemorrhage paramagnetic, we can make inferences about a lesion’s composition from 
these algorithms. 
The objective of this dissertation work was to characterize brain lesions, discovered with 
traditional imaging methods, as either hemorrhagic or calcific by using Dual-Energy Computed 
 vi 
 
Tomography (DECT) and Phase-Sensitive Magnetic Resonance Imaging (PS-MRI). To this 
end, MRI-compatible phantoms featuring models of both calcific and hemorrhagic lesions were 
developed and validated. This resulted in two phantoms with biologically similar lesion models 
that were then used to test the feasibility of differentiating calcific and hemorrhagic lesions with 
PS-MRI post-processing methods, in which QSM was able to accurately differentiate calcific 
and hemorrhagic lesion models. Finally, we undertook a patient trial testing the feasibility of 
identifying calcification and chronic hemorrhage in humans using both DECT and QSM in 
which the two modalities had accuracies of 99.7% (327/328) and 99.4% (326/328), 
respectively. The two modalities were concordant for 99.3% (148/149) lesions with SECT 
attenuation under 100 HU.  
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Chapter 1 
1 Introduction 
 
1.1 Significance 
Using Single-Energy Computed Tomography (SECT), both hemorrhagic and calcific 
lesions are hyperintense relative to the background brain tissue, and the CT numbers of both 
lesion types may overlap, depending on their composition and density. Lesions that have a CT 
number of over 100 Hounsfield Units (HU) on SECT are definitively calcific (1, 2); however, in 
the region of approximately 50 – 100 HU, the signal levels of hemorrhage and low-density 
calcifications overlap, and differentiation based on the CT number becomes unreliable. On 
conventional T2*-weighted Gradient Recalled Echo (GRE) Magnetic Resonance Imaging 
(MRI), both calcific and hemorrhagic lesions appear as black signal voids in the image known 
as foci of susceptibility, and the two material types are indistinguishable. GRE pulse sequences 
are highly sensitive to these lesion types, and foci of susceptibility are a common incidental 
finding on brain MRI. 
The presence of prior hemorrhage in the brain is a contraindication for anticoagulant 
therapies because they increase the risk of large brain bleeds. Additionally, certain disease 
profiles lend themselves towards either calcification or hemorrhage. Therefore, developing 
methods do distinguish calcific and hemorrhagic lesions allows for improved risk management 
and differential diagnosis amongst patients. 
 
1.2 Objectives and Hypothesis 
The objective of this project is to characterize brain lesions, discovered with traditional 
imaging methods, as either hemorrhagic or calcific by using Dual-Energy Computed 
Tomography (DECT) and Phase-Sensitive Magnetic Resonance Imaging (PS-MRI). These 
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modalities may increase or improve the information available to the radiologist regarding 
differential diagnosis and clinical management. Hemorrhagic lesions carry a risk of further 
bleeds while calcifications are generally benign. The central hypothesis is that DECT and 
PS-MRI can be used to accurately classify foci of susceptibility detected on 
conventional MRI as either hemorrhage or calcification.  
 
1.3 Specific Aims 
To test the central hypothesis, we have developed the following three specific aims: 
Specific Aim 1: Design and construct an MRI-compatible phantom with calcific and 
hemorrhagic lesion models. 
Subaim 1.1: Design and build an MRI-compatible phantom with varying densities of 
calcium and iron. 
Subaim 1.2: Validate the phantom materials with conventional SECT, conventional 
MRI, DECT, and PS-MRI. 
Subaim 1.3: Construct a final MRI-compatible phantom with calcific and hemorrhagic 
lesion models within biological constraints. 
Specific Aim 2: Optimize the imaging acquisition schema and post-processing methods to 
maximize the specificity of calcification and hemorrhage classification. 
Specific Aim 3: Conduct a human trial comparing the identification of intracranial calcification 
and hemorrhage using DECT and PS-MRI in vivo. 
Subaim 3.1: Compare the accuracy of DECT and PS-MRI for identification of known 
intracranial calcifications (lesions measuring greater than or equal to 100 HU on SECT). 
Subaim 3.2: Assess the concordance of DECT and PS-MRI for identification of 
intracranial hemorrhage and calcification measuring less than 100 HU on SECT. 
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1.4 Dissertation Organization 
This dissertation is organized in the following way: Chapter 2 provides background 
information on hemorrhagic and calcific lesions, DECT, and PS-MRI techniques. Chapter 3 
details Specific Aim 1 and presents the results of the MRI-compatible calcification and 
hemorrhage phantom experiments. Chapter 4 addresses Specific Aim 2 and covers the 
development of the pulse sequences and the mathematical models used to differentiate 
calcification and hemorrhage. Chapter 5 covers Specific Aim 3 and the results of a clinical trial 
comparing the use of DECT and PS-MRI in vivo. Lastly, Chapter 6 summarizes the dissertation 
and future avenues for this work. 
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Chapter 2 
2 Background 
 
2.1 Rationale 
2.1.1 Intracranial Hemorrhage 
Intracranial hemorrhage (ICH) is associated with a wide variety of etiologies, including—but not 
limited to—brain tumors, aneurysms, arteriovenous malformations, and hypertension (3, 4). In 
our patient population within a large, academic cancer hospital, we are particularly concerned 
with hemorrhage within brain malignancies as well as cavernous malformations, a type of 
venous malformation that is a common incidental finding on brain Magnetic Resonance 
Imaging (MRI) (5-7). Both lesion types may lead to clinically significant intracranial bleeding. 
 
Cavernous malformations, also known as cavernomas or cavernous angiomas, are mulberry-
shaped bundles of blood vessels that are often asymptomatic (8-11). Cavernomas are found in 
0.4-0.8% of the general population, and most are found incidentally on MRI (7, 12, 13). 
However, de novo development of cavernous malformations following cranial radiation therapy 
has been well documented in the literature (14-18). Amongst long-term survivors of childhood 
malignancy treated with cranial irradiation, the incidence of cavernoma is estimated to be 
between 3.0% and 31.5% (17-22). While there is a wide reported range of the frequency of 
cavernomas amongst cancer survivors, this may be caused by differences in the follow-up time 
and imaging techniques used in the reported studies. Cavernomas also carry an inherent risk 
of larger clinical bleeds of 0.7 – 6.5% per person-year in prospective studies (9-11, 13, 23, 24). 
The results of these studies can be found in Table 2.1. A study by Salman et al found that the 
5-year risk of mortality due to a cavernous malformation hemorrhaging was 4.5% (25). 
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Table 2.1: Summary of hemorrhagic event risk in patients with cavernous malformation. 
Authors & Year Number of 
Patients 
Hemorrhage 
Rate/Patient-Year 
(%) 
Re-hemorrhage 
Rate/Patient-Year (%) 
Moriarity et al., 1999 (13) 68 3.1 NA 
Kondziolka et al., 1995 (10) 122 1.3 4.5 
Zabramski et al., 1994 (9) 31 6.5 NA 
Flemming et al., 2012 (23) 292 2.25 6.19 
Salman et al., 2012 (25) 139 2.4 (5-year risk) 29.5 (5-year risk) 
Labauge et al., 2001 (11) 33 4.3 NA 
 
The appearance of ICH on MRI and CT changes over time. ICH evolves through the following 
phases: hyperacute (< 12 hours since onset), acute (12 hours to 2 days), early subacute (2-7 
days), late subacute (8 days to 1 month), and chronic (> 1 month) (26). Hyperacute 
hemorrhage consists primarily of fluid with blood products, including hemoglobin, and has an 
attenuation of 40 – 60 Hounsfield Units (HU) (3, 26). As the lesion progresses through the 
acute and early subacute states, clotting begins, the hematocrit level rises, and globin and 
fibrin form, causing increases in x-ray attenuation to between 60 and 80 HU (3, 26). In the early 
subacute phase, the clot retracts and further increases in attenuation up to approximately 100 
HU before cell lysis begins and the protein structures of the clot are broken down, causing the 
attenuation to decrease through the late subacute stage until the lesion becomes chronic (3, 
26).  
 
While the CT appearance of hemorrhage depends primarily on the density of the clot and the 
associated iron levels, the MR appearance depends on the pulse sequence used and the form 
of hemoglobin—or its byproducts—present at the time of imaging (Table 2.2). In the subacute 
phase, oxyhemoglobin dominates the MRI signal in the lesion; the signal in the acute phase is 
due to deoxyhemoglobin (3, 26). Deoxyhemoglobin is metabolized to methemoglobin, which is 
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present within the intracellular compartment in the early subacute phase and is transferred to 
the extracellular space as cell lysis begins in the late subacute phase (3, 26). Finally, the 
methemoglobin is metabolized, and the iron is stored in hemosiderin deposits surrounding the 
rim of the lesion (3, 26). 
Table 2.2: Single-Energy CT and conventional MRI image properties of intracranial 
hemorrhage by stage.  
ICH Stage 
CT 
Attenuation 
(HU) 
Hemoglobin 
Product 
T1-weighted 
MR 
T2-weighted 
MR 
T2*-weighted 
GRE MR 
Hyperacute 40 – 60 Oxyhemoglobin 
Isointense or 
Slightly 
hyperintense 
Hyperintense 
Hypointense 
Rim 
Acute 60 – 80 
Deoxy-
hemoglobin 
Isointense or 
hypointense 
Hypointense 
Hypointense 
Rim 
Progressing 
to Center 
Early 
Subacute 
80 – 100 
Intracellular 
Methemoglobin 
Hyperintense Hypointense Hypointense 
Late 
Subacute 
Decreasing 
0.7 – 1.5 
HU/day 
Extracellular 
Methemoglobin 
Hyperintense Hyperintense Hypointense 
Chronic 25 – 35 HU Hemosiderin 
Isointense or 
Hypointense 
Hypointense 
Hyperintense 
or Isointense 
Core with 
Hypointense 
Rim 
Note: Table adapted from reference (26) with additional data from reference (3). 
 
2.1.2 Intracranial Calcification 
Intracranial calcifications are a common incidental—and often normal—finding on imaging 
examinations of the brain (27). The most common forms include calcification of the pineal 
gland, which affects up to 40% of the population by age 20 (27), the choroid plexus (28), and 
dura mater (29). The incidence of these physiologic calcifications increases with patient age 
(27). Other types of calcification are a symptom of metabolic disorders, congenital or acquired 
infections, parasitic disease, and both benign and malignant brain tumors (30-35). Disorders of 
the parathyroid are associated with calcifications of the basal ganglia, subcortical white matter, 
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thalami, and cerebellum (33-35). Examples of congenital etiologies featuring intracranial 
calcifications include neurofibromatosis type II and Sturge-Weber syndrome (36-38). Infections 
such as Human Immunodeficiency Virus (39), tuberculosis (40, 41), and the parasitic disease 
neurocysticercosis (42) are also commonly associated with multiple calcifications within the 
brain parenchyma.   
 
In the realm of cancer diagnosis and treatment, the presence of calcification is particularly 
important for differentiating oligodendroglioma from other brain cancers or benign intracranial 
lesions. Up to 90% of oligodendrogliomas contain calcium deposits, while the majority of other 
brain malignancies, including glioblastoma multiforme, typically do not (31, 32, 43). Additionally, 
calcifications are a long-term effect of past radiotherapy to the brain and can be caused by 
certain chemotherapies (44). Unlike intracranial hemorrhage, calcifications within the brain 
typically do not cause morbidity to the patient.  
 
On conventional T1- and T2-weighted MRI, calcifications do not consistently provide the same 
signal intensity relative to normal tissue (45). Dense calcifications have low water content, 
which lowers the available MR signal (46); meanwhile, diffuse calcifications may shorten T1 
and T2 due to water’s interaction with the porous surface of the calcium salts (47). On T2*-
weighted MRI, calcium is consistently hypointense but can mimic microbleeds or hemorrhages. 
On CT, a signal measurement of over 100 HU is a definitive marker for calcification (2); 
however, diffuse calcifications may have CT numbers less than 100 and may mimic 
hemorrhagic lesions using conventional SECT. 
2.1.3 Anticoagulant Use among Cancer Patients 
The risk of venous thromboembolism is increased for patients with cancer over those in the 
general population, even in ambulatory patients, with rates of 4.1 to 7.4% (48-52). Inpatient 
treatment of cancer leads to further increases in the likelihood of morbidity or mortality due to 
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thromboembolism. Consequently, oncology patients are frequently prescribed prophylactic 
anticoagulation to minimize the occurrence of deep vein thrombosis and pulmonary embolism 
(53-55). While this lowers overall morbidity from complications of cancer and its treatment, care 
must be taken to appropriately use prophylaxis because of the risk of inducing a hemorrhagic 
stroke. 
 
The risk of bleeding from cavernous angiomas while on anticoagulant therapy has not been 
well defined. Recently, several investigators have attempted to determine the risk associated 
with antithrombotic therapies in patients with cavernomas. In a cohort of 292 patients with 
diagnosed cavernomas studied by Flemming et al, only six patients were placed on 
anticoagulant therapy, and no prospective or recurrent bleeds were recorded amongst those 
patients (56). Schneble et al also found that there were no hemorrhages in 26.4 person-years 
of observation amongst five patients with diagnosed cavernoma that were prescribed warfarin 
(57). However, there have been several documented case studies of cavernous angioma 
bleeds occurring in patients receiving antithrombotic therapy, including one instance of a known 
asymptomatic cavernoma hemorrhaging following treatment with low-molecular weight heparin 
following surgery (58, 59). Overall, due to the small sample sizes in these studies, the results 
cannot be considered conclusive (57, 60, 61). 
 
Anticoagulant use is contraindicated in patients that have had prior bleeds within the brain 
because the risk of large, symptomatic hemorrhage is increased following smaller bleeds that 
may have been asymptomatic and found incidentally. These include all lesions that may have 
indications of chronic or acute hemorrhage on imaging exams of the brain, including, but not 
limited to venous malformations, primary brain tumors, and hemorrhagic metastases of the 
brain.  
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2.2 DECT Implementations and Image Reconstruction 
Dual-Energy Computed Tomography (DECT) provides unique opportunities to differentiate 
materials in the human body. The theoretical underpinnings of DECT were developed in the 
late 1970s and first implemented in the 1980s (62-67). However, due to limitations in the CT 
hardware and computing power, the potential of DECT was not fully realized until the first 
commercial dual-source CT scanner was released in 2005 (68). As of 2018, the major 
manufacturers have added DECT capabilities to at least one of their commercially available CT 
systems, and have independently developed variations on the hardware used to acquire DECT 
exams and the software used to analyze the data (69). 
 
DECT is based upon the premise that the CT number, measured in Hounsfield Units (HU), 
varies with x-ray energy (E) according to the following equation (70): 
 
𝐶𝑇 𝑁𝑢𝑚𝑏𝑒𝑟 = 1000 ×
𝜇𝑥(𝐸) − 𝜇𝑤𝑎𝑡𝑒𝑟(𝐸)
𝜇𝑤𝑎𝑡𝑒𝑟(𝐸)
 Equation 2.1 
where 𝜇𝑥 represents the linear attenuation coefficient of an unknown material x and 𝜇𝑤𝑎𝑡𝑒𝑟 is 
the linear attenuation coefficient for water. The linear attenuation coefficient is a function of x-
ray energy and depends on the material. For example, iodine—commonly used in clinical CT 
contrast agents—has a very high attenuation coefficient at low x-ray energies due to the 
prevalence of photoelectric interactions with high Z materials, and the attenuation decreases as 
the energy decreases due to Compton scatter becoming the predominant interaction at higher 
energies. For low Z materials such as water, the attenuation coefficient is much more stable 
with x-ray energy. The difference in the shapes of these curves allows for the differentiation of 
materials with the use of two or more energy spectra (Figure 2.1). 
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Figure 2.1: Linear attenuation coefficients for water, cortical bone, and Omnipaque 350 
(iodinated contrast agent) demonstrating differences in the material attenuation 
properties across a range of diagnostic x-ray energies. In this example, cortical bone 
could be described as a linear combination of water and Omnipaque. 
2.2.1 DECT Hardware Implementation 
There are six major hardware implementations of DECT currently available in the marketplace. 
The first commercially available DECT was a dual-source (DS) system with two x-ray tube and 
detector arrays, which allowed for scanning with two separate energies (Figure 2.1b). The first 
system of this type became available in 2005 (Definition, Siemens Healthineers, Forchheim, 
Germany), and there have been two additional dual-source scanners released as of 2018 
(Definition Flash and Definition Force, Siemens). There are several advantages to this type of 
system. First, the potential spectral separation is maximized because there are two separate x-
ray spectra, and additional filtration can be placed on one or both tubes to separate the spectra 
further (71, 72). Since its first release, there have been two additional scanner models released 
using this hardware scheme—the Siemens Definition Flash and Definition Force scanners—
known as 2nd and 3rd generation DS-DECT. One downside of these systems is that there is a 
temporal mismatch between projections at the low and high energy levels; additionally, 
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scattered radiation from one x-ray tube and detector pair can enter the other detector array, 
known as cross-scatter, and must be accounted for during the image reconstruction process. 
 
The second DECT hardware implementation to be released commercially was the fast peak 
kilovoltage (kVp) switching systems (Figure 2.2a) developed by General Electric Healthcare 
(HD750 and Revolution CT, GE Healthcare, Waukesha, WI). On these systems, the generator 
switches from 80 kVp to 140 kVp between alternating projections. This acquisition method 
allows for acquisition of DECT data in which the two spectra have a nearly perfect temporal 
agreement but limits the degree of spectral separation that is feasible because added filtration 
is not possible and data is acquired continuously during the kVp-switching process (73, 74). 
 
Figure 2.2: Schematics of DECT hardware implementations currently available, including 
a) fast kVp-switching, b) dual-source, c) dual-layer detectors, and d) split-filter systems.  
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Dual-layered detector DECT systems, such as the Philips IQon (Philips Healthcare, Best, The 
Netherlands), also utilize a single x-ray tube (Figure 2.2c). These systems operate at a single 
kVp, and the resulting data is split into two spectra by using a detector with two sets of 
electronics. The top layer of the detector preferentially absorbs low-energy photons, while high-
energy photons penetrate the first layer and are absorbed in the bottom layer of the detector. 
The resulting data can either be used to create low- and high-energy image sets and DECT 
reconstructions or the data acquired by the two layers can be combined to reconstruct a 
conventional SECT image (75-78). It is unclear how well this method separates the spectra 
since a high-energy photon could be scattered in the first layer, depositing a portion of its 
energy in each detector layer. However, these systems are advantageous for performing 
comparisons of DECT and conventional SECT (75) since DECT data can be stored for every 
exam for later processing as needed without burdening radiologists with additional image 
series. 
 
Split-filter systems operate in dual-energy mode with a single x-ray tube run at 120 kVp but 
create two different energy spectra along the z-axis of the scanner via the addition of additional 
filtration (Figure 2.2d) (79, 80). Half of the supplementary filter is gold—softening the x-ray 
spectrum—and half is tin, which hardens the spectrum (81-84). This paradigm results in 
relatively little spectral separation, which may be further degraded by the presence of cross-
scatter. The available technique parameters are limited to helical scans with a low pitch to 
obtain adequate photon counts in each energy bin. Additionally, these filters may induce 
artifacts in the images when the air outside the body is included within the region of helical over 
ranging due to the interpolation required to combine the data from various times and locations 
along the z-axis. The poor temporal matching between the high and low energy projections 
may also limit the use of certain reconstruction algorithms, and the long scan times make this 
dual-energy technique more susceptible to motion artifacts. 
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There are also systems designed to incorporate slow kVp-switching to acquire DECT data. 
These scanners acquire two consecutive rotations at the same z-location at two different 
energies. This method is utilized by the Canon (formerly Toshiba) Acquilion One CT (Canon 
Medical Systems, Otawara, Japan) (85). This scanner is capable of scanning whole organs in 
one rotation, which minimizes the chances of motion artifacts between projections. However, 
there is still a temporal mismatch between the high and low energy projections. Compared to 
fast kVp-switching, there is the potential for better spectral separation, but there has been 
relatively little research performed using this DECT methodology to date (86-91). 
 
Finally, there are scanners which can perform DECT acquisitions by first acquiring a scan at 
low energy followed by a scan at higher energy (69, 92). While this is a highly cost-effective 
option and provides very good spectral separation, it is particularly sensitive to patient motion, 
and cannot be used to assess iodine concentrations in tissue because of the timing differences 
between the two scans. 
2.2.2 DECT Software Implementations 
DECT data is processed either through projection-based methods, which are performed on the 
raw sinogram data prior to image reconstruction (93-96) or by image-based methods that first 
reconstruct low- and high-energy images and subsequently calculate DECT properties (97, 98).  
 
Projection-based methods require temporal co-registration of the low- and high-energy 
datasets; the fast kVp-switching and dual-layer detector systems utilize this approach to DECT 
reconstruction. In these algorithms, DECT data is derived using basis material decomposition, 
which posits that any material can be modeled as a linear combination of the attenuation 
coefficients of two predefined materials, the proof of which is shown here. X-ray attenuation 
depends on two primary mechanisms in the diagnostic energy range: photoelectric effect and 
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Compton scattering, the fraction of scatter caused by each mechanism is defined as 𝑓𝑃𝐸  and 𝑓𝐶 , 
respectively. Both 𝑓𝑃𝐸  and 𝑓𝐶  depend on the x-ray energy, 𝐸. Therefore, the linear attenuation 
coefficient (𝜇) of any material can be defined as a linear combination of the attenuation due to 
each of those effects (Equation 2.2). 
 𝜇(𝐸) = 𝛼𝑓𝑃𝐸(𝐸) + 𝛽𝑓𝐶(𝐸) Equation 2.2 
Therefore, the attenuation of the basis materials 1 and 2 gives us the following system of 
equations: 
 
{
𝜇1(𝐸) = 𝛼1𝑓𝑃𝐸(𝐸) + 𝛽1𝑓𝐶(𝐸)
𝜇1(𝐸) = 𝛼2𝑓𝑃𝐸(𝐸) + 𝛽2𝑓𝐶(𝐸)
 Equation 2.3 
Solving Equation 2.3 for the photoelectric and Compton scatter fractions returns Equation 2.4 
and Equation 2.5:  
 
𝑓𝑃𝐸(𝐸) =
𝛽2𝜇1(𝐸) − 𝛽1𝜇2(𝐸)
𝛼1𝛽2 − 𝛼2𝛽1
 Equation 2.4 
 
𝑓𝐶(𝐸) =
𝛼2𝜇1(𝐸) − 𝛼1𝜇2(𝐸)
𝛼2𝛽1 − 𝛼1𝛽2
 Equation 2.5 
Equation 2.4 and Equation 2.5 define the photoelectric and Compton scatter fractions in terms 
of the attenuation of materials 1 and 2. Substituting these back into Equation 2.2 returns: 
 
𝜇(𝐸) = 𝛼(
𝛽2𝜇1(𝐸) − 𝛽1𝜇2(𝐸)
𝛼1𝛽2 − 𝛼2𝛽1
) + 𝛽(
𝛼2𝜇1(𝐸) − 𝛼1𝜇2(𝐸)
𝛼2𝛽1 − 𝛼1𝛽2
) Equation 2.6 
Equation 2.6 is algebraically equivalent to Equation 2.7.  
 𝜇(𝐸) = 𝑎1𝜇1(𝐸) + 𝑎2𝜇2(𝐸) where 
𝑎1 =
𝛼𝛽2 − 𝛽𝛼2
𝛼1𝛽2 − 𝛼2𝛽1
 and 𝑎2 =
𝛽𝛼1 − 𝛼𝛽1
𝛼1𝛽2 − 𝛼2𝛽1
  
Equation 2.7 
The attenuation coefficients of materials 1 and 2 are known a priori. Measuring the attenuation 
of the voxel in question at two energy levels returns a system of two equations with two 
unknowns that can be solved to determine the amount of materials 1 and 2. The resulting 
quantities of each material, which can be given in terms of density, represent the amounts of 
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each material that would be required to model that voxel’s attenuation properties (Equation 
2.8). 
 
{
𝜇(𝐸𝑙𝑜𝑤) = 𝑎1𝜇1(𝐸𝑙𝑜𝑤) + 𝑎2𝜇2(𝐸𝑙𝑜𝑤) 
𝜇(𝐸ℎ𝑖𝑔ℎ) = 𝑎1𝜇1(𝐸ℎ𝑖𝑔ℎ) + 𝑎2𝜇2(𝐸ℎ𝑖𝑔ℎ)
 Equation 2.8 
It should be noted that while the basis materials can be chosen by the user, the two materials 
selected must have sufficiently different attenuation properties in order to achieve an accurate 
classification of materials. It is optimal to have one low Z material—water or soft tissue—and 
one higher Z material—iodine or calcium. Additionally, users must be aware of the energy of 
the K-edge of the material. Since CT data is polychromatic, the energy range over which data 
is acquired is approximately 40 to 140 keV for a system with a maximum kVp of 140. As a 
result, if the K-edge of the material of interest falls within this range, the attenuation differences 
between the low- and high-energy measurements may not be large enough to calculate 
accurate material density estimates (Figure 2.3). 
 
Figure 2.3: Linear attenuation coefficients for gold (K-edge at 80.7 keV) and water. When 
the K-edge falls between 40 and 140 keV, it is possible that the measured attenuation at 
the low- and high-energies in DECT may return similar attenuation values. 
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Image-space DECT analysis is performed following reconstruction of low- and high-energy CT 
datasets (69, 99-101). All acquisition methods that cannot ensure temporal registration of the 
two datasets use image-based reconstruction. These algorithms may use up to three materials, 
which are mapped to predefined CT numbers in the low- and high-energy images and include a 
volume conservation term where the sum of the volume fractions of each material must equal 
one (96). Figure 2.4 shows a theoretical example of an abdominal virtual non-contrast 
algorithm where the three materials are soft tissue, fat, and iodinated contrast. For a given 
measured voxel, a, the point can be projected onto the line segment between the two low-
density tissues to point b along a second line originating from the defined iodine point. Point b 
represents the virtual non-contrast values for the voxel, and the distance between points a and 
b, the length i, is proportional to the amount of iodine present in the voxel. The value i can be 
presented as the attenuation in HU attributed to iodine enhancement or as an iodine 
concentration. While this theoretical example utilized iodine as a high Z material, different 
applications may utilize different materials than those depicted here. 
 
Figure 2.4: Schematic of image-based three material decomposition. Point a represents 
the CT numbers of a measured voxel at the low and high tube voltages. The measured 
values are then projected onto the line between fat and soft tissue values along the red 
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line. Thus, point b represents the virtual unenhanced CT numbers while i represents the 
amount of iodine present. 
2.3 DECT Applications 
2.3.1 Virtual Non-Contrast 
One of the primary clinical applications of DECT is the digital removal of the signal caused by 
the presence of iodine, known as Virtual Non-Contrast (VNC) or Virtual Unenhanced imaging 
(68, 102-105). VNC enables clinics to perform a single contrast-enhanced scan of a patient and 
produce a simulated non-contrast phase, which can help in efforts to lower patients’ exposure 
to ionizing radiation and lower the costs associated with CT imaging. Vendors typically provide 
a non-contrast or water image as well as an iodine map either in units of mg Iodine/mL 
(General Electric, Philips) or the HU attributed to iodinated contrast (Siemens).  
 
Many studies have been performed to assess the utility, image quality, and accuracy of virtual 
non-contrast images (103, 106-108). The resulting iodine maps have been used to differentiate 
between benign and malignant renal lesions (105, 109-112), identify metastatic disease in 
lymph nodes (113-116), and improve visualization of pancreatic (117, 118) and gynecological 
cancers (119). One common application of DECT virtual non-contrast imaging in neurology is 
the differentiation of hemorrhage from residual iodinated contrast agent following mechanical 
thrombectomy in patients with ischemic stroke (120-123). 
 
Although these images may be useful clinically, there are disadvantages of which users must 
be aware. When choosing materials for virtual non-contrast image processing, vendors use 
iodine as the high-Z material in their processing algorithms and either one or two soft tissue-like 
materials (water, soft tissue, fat, etc.). Materials must be classified as a linear combination of 
these materials. Therefore, other high-Z materials such as calcium appear in both the virtual 
non-contrast and the iodine map provided by the vendors. 
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2.3.2 Virtual Monoenergetic Images 
DECT data may also be used to create virtual monoenergetic images that simulate images 
acquired with a monoenergetic x-ray source (67, 92, 124-126). Users can reconstruct images 
at any energy between 40 keV and either 140 keV on GE systems or 190 keV on Siemens and 
Philips systems. To create these images, the density of the low-Z material (soft tissue or water) 
and iodine are calculated as detailed in section 2.2.2 for each voxel. Then, using the 
attenuation coefficient of each material, as defined by the National Institutes of Standards and 
Technology (NIST), is used in the following equation to estimate the total attenuation coefficient 
at the user-defined energy. 
 𝜇𝑡𝑜𝑡𝑎𝑙(𝐸) = (
𝜇
𝜌
)
𝐿
(𝐸) ∙ 𝜌𝐿 + (
𝜇
𝜌
)
𝐻
(𝐸) ∙ 𝜌𝐻 Equation 2.9 
 
2.3.3 Calcium Identification 
Since calcium is a high Z material with a low K-edge, calcium can be readily identified using 
material decomposition, which is particularly useful because calcium and iodine can have very 
similar attenuation levels using SECT. DECT, therefore, enables more accurate removal of 
bony anatomy and removal of calcific plaques to improve visualization on CT angiography (84, 
127, 128). Additionally, virtual calcium removal can lead to visualization of bone marrow edema 
in fractures that may otherwise be difficult to diagnose without MRI (89, 129-132). Material 
decompositions that incorporate calcium also enable quantitative estimates of calcium density, 
which have been utilized to estimate bone mineral density (133, 134).  
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2.3.4 Distinguishing Calcification and Hemorrhage 
 
Figure 2.5: Attenuation curves for dense calcification (as modeled by low density cortical 
bone) and whole blood products. Note that blood products have a very similar curve 
shape as water with a slightly higher overall density. 
There have been several studies published in the literature regarding the differentiation of 
intracranial calcification from hemorrhage (135-138). First were two phantom studies by Nute et 
al. demonstrating the feasibility of distinguishing these lesion types quantitatively using a 
calcium and water material decomposition on a fast kVp-switching system (135, 136).  Both of 
these studies utilized an anthropomorphic head phantom and simulated calcific and 
hemorrhagic lesions by doping agarose (135) and brain attenuation-equivalent epoxy-resin 
(136) with calcium hydroxyapatite and iron oxide. Based on the attenuation curves for blood 
products and bone, the authors found that by using a decomposition of calcium and water, a 
plane of differentiation could be calculated that optimally separated the lesion types, as shown 
in Figure 2.6 (136). Differentiation was possible primarily using the water(calcium) images, in 
which hemorrhagic lesions would be iso- or hypo-intense, and calcific lesions would be 
hyperdense (Figure 2.7). Using this method, they found that differentiation was possible at 
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signal levels of 50 and 60 HU for 1.5cm and 1.0cm lesions in the cerebrum at 90% accuracy 
(136).  
 
Figure 2.6: Example of a plane of differentiation developed with geometric bisectors for a 
1.5cm diameter lesion in the cerebrum, imaged at 132.5 mGy and reconstructed at 5 mm 
image thickness with a soft filter. Voxel data for the hemorrhagic lesions are shown in 
red, while voxel data for the calcific lesions are shown in gray.  
 
Lesion differentiation was also tested on a dual-source DECT system in an emergency 
department where all patients with suspected stroke underwent DECT imaging of the head 
(137). They found that a 3-material decomposition using calcium, brain tissue, and hemorrhage 
was capable of identifying calcific lesions because they were completely removed from the 
virtual non-calcium images while the signal in hemorrhagic lesions was visualized in both the 
calcium and soft tissue images. The authors confirmed the presence of hemorrhage on follow-
up MRI and CT imaging (139). This technique, while not quantitative, had a sensitivity of 96% 
and specificity of 100% for the detection of hemorrhage (137). 
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Figure 2.7: DECT reconstructions of a) 68 keV, b) calcium(water), and c) water(calcium) in 
a phantom image acquired at 132.6 mGy CTDIvol with 5 mm slice thickness and a soft 
reconstruction filter. Lesion models in the phantom were 80 HU at 120 kVp SECT. Solid 
arrows indicate calcific lesions while unfilled arrows identify iron-based lesion models. 
 
2.4 Magnetic Susceptibility 
Magnetic susceptibility is an inherent property of any material represented by a dimensionless 
scalar (χ). It represents the extent to which the material magnetizes when placed in a magnetic 
field, and is equal to the magnetization of the object divided by the magnetic field strength. 
Ferromagnetism is a unique property of certain compounds in which the material remains 
magnetized after being removed from an external magnetic field caused by both the chemical 
make-up of the material and a particular crystal structure. Ferromagnets are the magnetic 
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materials most commonly encountered in daily life, but are not present naturally within the 
human body; the forms of magnetism that are naturally occurring in humans are described 
below. 
2.4.1 Diamagnetism 
Diamagnetic materials repel or weaken a magnetic field within a given material and have a 
negative magnetic susceptibility. Water (χ = -9.035 x 10-6) and many tissues in the body are 
slightly diamagnetic (140). The most common usage of the term diamagnetic in the medical 
literature refers to materials with a susceptibility less than that of water, including calcium 
deposits (140-144). 
2.4.2 Paramagnetism 
Paramagnetic materials are also common within the human body. These materials have a 
positive susceptibility, so a magnetic field is locally strengthened in the material. For truly 
paramagnetic materials, the amount of magnetism is directly proportional to the strength of the 
applied field. Paramagnetism is caused by the spin of unpaired electrons within a material, and 
in total only a small portion of the spins orient with the field, so the effect is weak. Examples of 
materials that are paramagnetic relative to water are deoxyhemoglobin and iron deposits in the 
form of ferritin and hemosiderin. 
2.4.3 Superparamagnetism 
Superparamagnetism occurs in materials where very small individual paramagnetic particles 
each have an individual magnetic domain within a non-magnetic medium. These single domain 
particles each have their own magnetic moment, and together the total moment, when exposed 
to a magnetic field, is orders of magnitude higher than that of a typical paramagnet. The effect 
is present because materials with larger particles tend to form grains of magnetic materials that 
interact with each other and do not individually align with the applied magnetic field. One 
example of this phenomenon is superparamagnetic iron oxide nanoparticles (diameter < 30 
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nm), which have a much higher susceptibility for a given iron concentration than iron oxides 
with larger particles (145). 
2.5 MRI Phase Basics 
The Magnetic Resonance Imaging (MRI) data required to form an image comes from the spin 
precession of hydrogen nuclei, known as the Proton Resonance Frequency (PRF). To fully 
describe the location of the precessing spins, the data is acquired in quadrature, meaning that 
the signal acquired is acquired along two orthogonal directions (146, 147). The signal can be 
modeled as a complex number, where one channel is labeled “real” and the other “imaginary” 
(Figure 2.8). 
 
Figure 2.8: Diagrammed relationship between the MRI signal (S), the components 
measured in the real (Re) and imaginary (Im) channels, and the magnitude and phase of 
the signal. 
The signal can also be expressed in the rotating frame of reference in terms of its magnitude, 
|𝑆|, and phase angle, 𝜑:  
 𝑆 = |𝑆|𝑒𝑖𝜑 Equation 2.10 
The exact magnitude of the signal depends on the magnetic field strength, the pulse sequence 
used, and the following material properties: T1, T2, T2*, and proton density. The proton density 
is proportional to the number of hydrogen atoms in the voxel of interest. T1 represents the rate 
at which longitudinal magnetization is regained following excitation into the transverse plane by 
an RF pulse. T2 is the rate at which the transverse magnetization dephases based on nuclear 
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interactions only, whereas T2* is the observed relaxation rate when accounting for magnetic 
field inhomogeneities, and T2’ is proportional to the change in the local magnetic field at the 
inhomogeneity (Equation 2.11). 
  1
𝑇2∗
=
1
𝑇2
+
1
𝑇2′
 Equation 2.11 
 
Phase is measured over the range of [-𝜋, 𝜋], so a true phase value of 2𝜋 would be mapped to a 
measured phase of 0. This results in an effect called phase wrapping, in which sharp 
boundaries in the phase image occur between a phase of -pi and +pi, as depicted in Figure 2.9. 
 
Figure 2.9: The MRI phase image displayed depicts phase wrapping at boundaries 
between -pi and pi. Additionally, noise is amplified in low signal regions of the image. 
2.5.1 Gradient Recalled Echo Pulse Sequences 
Gradient recalled echo (GRE) pulse sequences are used when the application requires fast 
scanning or scanning of a large volume, including but not limited to perfusion, angiographic, 
and cardiac imaging. Following the initial RF excitation pulse, the free induction decay signal is 
rephased for readout using a gradient pulse. Spin echo sequences that utilize a 180° RF pulse 
to refocus the signal also refocus off-resonance effects caused by local magnetic field 
inhomogeneities (70, 146). GRE sequences cannot refocus these spins that are resonating off 
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of the expected frequency, and so these cause artifacts in the images. As a result of these off-
resonance effects, GRE sequences are T2*-weighted rather than T2-weighted, and regions 
with differences in susceptibility relative to the background are emphasized because they 
change the local magnetic field. The echo time (TE), repetition time (TR), and flip angle (𝛼) of 
the pulse sequence determines the exact weighting of the sequence, and the signal of a 
spoiled GRE is also dependent on the T1 and T2* of a material, and is adjusted by a scaling 
factor f:  
 
𝑆(𝑇𝐸) = 𝑓
sin𝛼 (1 − 𝑒−𝑇𝑅/𝑇1)
(1 − cos𝛼 ∙ 𝑒−𝑇𝑅/𝑇1)
𝑒−𝑇𝐸/𝑇2
∗
 Equation 2.12 
Despite the number of factors that impact the image weighting, TE is the primary factor that will 
influence the degree of T2* weighting in the final image, and lower TE images will feature 
higher SNR and fewer susceptibility artifacts than those images with higher TE. 
 
2.5.2 Magnetic Susceptibility and MRI Phase 
As described in section 2.4, paramagnetic and diamagnetic materials increase and decrease 
the magnetic field, respectively. The effective magnetic field (𝐵𝑒𝑓𝑓) is defined by the following 
equation, where 𝐵0 is the strength of the main magnetic field, and ∆𝜒 is the difference in the 
susceptibility compared to that of the background (148).  
 𝐵𝑒𝑓𝑓 = (1 + ∆𝜒)𝐵0 Equation 2.13 
The effective magnetic field in the region with differing susceptibility causes the spins to 
precess at a slightly different rate from the spins present in normal tissue. Therefore, at the TE 
in a GRE sequence—in which these spins are not rephased by a 180° RF pulse—there is an 
accumulation of phase in accordance to the following equation (148): 
 𝜑(𝑡) = −𝛾𝐵0(𝑇𝐸 + ∆𝜒) Equation 2.14 
 
The true phase can, therefore, be used to estimate the susceptibility of a lesion. However, 
there are confounding factors that must be accounted for to calculate the correct phase value 
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for a given voxel. First, phase wraps (Section 2.5) must be eliminated by one of various phase 
unwrapping algorithms, which becomes increasing challenging as the number of spatial 
dimensions increases (149-151). Once phase wraps are successfully removed, the image is an 
estimate of the magnetic field perturbation (152). Additionally, there are background phase 
variations caused by non-local effects such as inhomogeneities in B0, large susceptibility 
differences (for example, air-tissue interfaces), and eddy currents (153, 154). The simplest 
method of removing the background phase is to use a high-pass filter to remove the low 
frequency components of the image (155, 156). Other methods have estimated the background 
phase using polynominal fitting (157-159), forward calculations using a priori knowledge of the 
background susceptibility distribution (160), and models of magnetic dipole sources outside of 
the region of interest (154) in attempts to model the phase more accurately.  
2.6 Susceptibility-Weighted Imaging 
Susceptibility-weighted imaging (SWI) is a technique for improving the visualization of veins 
and other high-susceptibility tissues (Figure 2.10). The method utilizes a background 
subtracted phase image to create an image mask, usually created by passing a high-pass filter 
over the phase image (161). Following background phase removal, the phase mask is created 
by scaling the phase using the following equation (162): 
 
𝑓(𝑥) = {
𝜋 + 𝜑(𝑥)
𝜋
, −𝜋 < 𝜑(𝑥) < 0
1, otherwise
 Equation 2.15 
where 𝑥 specifies voxel location and 𝜑(𝑥) is the phase at that location.  The magnitude image 
𝜌(𝑥) is utilized to create the susceptibility-weighted image 𝜌(𝑥) according to the formula: 
 𝜌(𝑥) = 𝑓𝑛(𝑥) ∙ 𝜌(𝑥) Equation 2.16 
In which 𝑛 represents the number of times the phase mask is multiplied by itself, and is chosen 
to change the susceptibility weighting and optimize the signal to noise ratio (SNR) (161, 163). It 
has been shown that 𝑛 = 4 provides an optimal balance between enhancing the image contrast 
of venous structures while maintaining SNR (164). 
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Figure 2.10: Susceptibility-weighted imaging (SWI) improves visualization of venous 
structures, as shown by comparison of a T2*-weighted GRE (a), Susceptibility-Weighted 
Angiography (b). The high-pass filtered phase image (c) from the SWAN sequence 
emphasizes the local magnetic field changes near the susceptibility lesion (black 
arrows). 
The typical scaling of SWI does not differentiate between negative and positive phase 
accumulation. As a direct result, calcification and hemorrhage cannot be differentiated using 
the phase scaling in Equation 2.15. Other phase masks have been developed, such as a 
triangular mask that accounts for negative phase values (165); however, these are not 
commonly applied in SWI applications provided by MR vendors. 
 
2.7 Quantitative Susceptibility Mapping 
Quantitative Susceptibility Mapping (QSM) is an MRI phase-based post processing technique 
to reconstruct tomographic maps of magnetic susceptibility in tissue (148, 153, 162, 166). 
Following phase unwrapping and background phase removal, QSM solves an inverse problem, 
going from the measured magnetic field perturbation around a distribution of magnetic dipoles 
back to the susceptibility distribution that caused it (148). Because GRE pulse sequences are 
inherently sensitive to magnetic susceptibility, they are an obvious choice for QSM acquisitions. 
All QSM post-processing is vulnerable to noise in the phase images. High noise in the phase 
image is of particular concern in large hemorrhagic or calcific lesions where the signal is very 
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low, and thus noise is amplified significantly (Figure 2.9). As a result, multi-echo GRE 
sequences are most commonly used to acquire data for QSM processing because the phase 
can be calculated more accurately by assessing the temporal evolution of the phase as the TE 
changes, as shown in Figure 2.11 (152). 
 
Figure 2.11: A multi-echo gradient recalled echo sequence (magnitude image, a) is used 
to generate a background subtracted phase image (b) and a Quantitative Susceptibility 
Map (c). Note the pineal calcification (arrow) and a punctate paramagnetic lesion in the 
globus pallidus (arrowhead) that both appear hypointense in the magnitude image and 
can be differentiated in the QSM. 
2.7.1 Mathematical Derivation of the Inverse Problem 
A predefined magnetization distribution ?⃗? (𝑟 ), which is proportional to the distribution of the 
magnetic susceptibility, induces a magnetic field variation ∆?⃗? (𝑟 ), that is equal to 
 
∆?⃗? (𝑟 ) =
𝜇0
4𝜋
∫ {
3?⃗? (𝑟 ′)(𝑟 − 𝑟 ′)2
|𝑟 − 𝑟 ′|5
−
?⃗? (𝑟 ′)
|𝑟 − 𝑟 ′|3
}
𝑉
𝑑3(𝑟 ′) 
 
Equation 2.17 
where 𝑟  represents coordinates in Cartesian space and  𝜇0 represents the magnetic 
permeability in free space. We can assume that the main magnetic field resides solely in the z 
direction, so Equation 2.17 simplifies to: 
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∆𝐵𝑧(𝑟 ) =
𝜇0
4𝜋
∫ {
3𝑀𝑧(𝑟 
′)(𝑧 − 𝑧′)2
|𝑟 − 𝑟 ′|5
−
𝑀𝑧(𝑟 
′)
|𝑟 − 𝑟 ′|3
}
𝑉
𝑑3(𝑟 ′) 
 
Equation 2.18 
where ∆𝐵𝑧(𝑟 ) is the magnetic field variation along the z-axis. Equation 2.18 can be represented 
as a convolution of the magnetization distribution with the magnetic dipole kernel, ?⃗? (𝑟 ). 
 ∆𝐵𝑧(𝑟 ) = 𝜇0𝑀𝑧(𝑟 ) ∗ 𝐷(𝑟 ) 
= 𝜇0𝑀𝑧(𝑟 ) ∗ [
1
4𝜋
3 cos2 𝜃 − 1
𝑟 3
] 
Equation 2.19 
 
From this point, we assume that the susceptibility at any given point is sufficiently small to 
assume that 𝑀𝑧(𝑟 ) ≈ 𝐵0𝜒(𝑟 )/𝜇0. The problem is better posed in the frequency domain (k-
space), so the Fourier transform is taken (𝐷(?⃗? ) = 𝐹𝑇{𝐷(𝑟 )}), and the convolution theorem is 
applied to Equation 2.19, returning the desired inverse problem, in which ?⃗?  represents a vector 
in frequency space and 𝑘𝑧 is the z-component of the vector. 
 
∆𝐵𝑧(?⃗? ) = 𝐵0𝜒(?⃗? ) × 𝐷(?⃗? ) Equation 2.20 
 
𝐷(?⃗? ) =
1
3
−
𝑘𝑧
2
|?⃗? |
2 
Equation 2.21 
Since ∆𝐵𝑧(𝑟 ) is measured and the remaining quantities are known, the inverse problem can be 
solved to calculate the distribution of 𝜒(𝑟 ). However, in k-space, the dipole moment (Equation 
2.21) is equal to zero along a cone at an angle of 54.7° (hence known as the “zero cone”), and 
therefore the problem is ill-posed (152, 153, 167-169).  
2.7.2 QSM Methods 
Because solving for the susceptibility distribution is ill-posed, many methods have been 
implemented to correct for the streak artifacts that would otherwise be induced by the zeros in 
the dipole moment. The gold standard for accurately measuring the susceptibility is 
“Calculation Of Susceptibility through Multiple Orientation Sampling,” or COSMOS (170-172). 
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The COSMOS technique requires multiple acquisitions of GRE data with the sample in different 
orientations to effectively average out the effect of the zero cone, ensuring that no point in k-
space is filled with zeros. Thus, the inverse problem can be solved directly. This method is 
highly accurate but time consuming and difficult for many body regions outside of the 
extremities and the head. 
 
Because of the logistical constraints of implementing COSMOS for QSM measurements in 
vivo, multiple processing methods have been developed that utilize a single GRE acquisition to 
estimate the susceptibility. What these methods have in common is that they utilize some form 
of regularization. The first of these methods is Thresholded K-space Division (TKD), in which 
very small or zero values in the dipole kernel are replaced with a constant (173-176). This 
method reduces streaking artifacts caused by the zero cone, but it can induce artifacts 
elsewhere in the image if phase shifts are not caused by susceptibility. 
 
Several methods use iterative computational techniques to calculate a solution to the inverse 
problem. The difference between the measured magnetic field and the convolution of the dipole 
moment and calculated susceptibility distribution is computed first. The end goal is to minimize 
the sum of the L2 norm of this difference and a regularized prior information term. The prior 
information completes the missing data in k-space. Other similar techniques include using a 
sparse linear equation and least squares (LSQR) approach (177, 178), piecewise constant 
regularization (157), non-linear regularization of the susceptibility gradients (179, 180), and 
methods requiring anatomical or morphological agreement (167, 181). Morphology-Enabled 
Dipole Inversion (MEDI) is the most prominent QSM method using this scheme. The prior 
information in MEDI is taken from the magnitude images, and edges in the magnitude image 
are assumed to correspond with true edges in the calculated susceptibility map (167, 182, 
183). Disadvantages of this technique include mismatches in the calculated susceptibility 
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values where the anatomic edges and edges in the true susceptibility distribution do not match 
(152). 
 
A final group of algorithms only fills in ill-conditioned k-space data rather than using prior 
information to inform the whole dataset. These methods split k-space into various subdomains, 
and the ill-conditioned portions are reconstructed separately from the other domains. The 
susceptibility distribution is optimized subject to either a sparse L1 norm or total variation norm 
(152). The Homogeneity-Enabled Incremental Dipole Inversion (HEIDI) technique is one 
particular example of this subdomain-based QSM method (184). These methods tend to be 
quite accurate when compared to COSMOS and eliminate streak artifacts effectively (184). 
2.7.3 QSM Applications 
The primary sources of susceptibility in human tissues are iron, calcium, lipids, and myelin 
(140, 185). While there has not been an investigation to date using QSM to quantify the fat 
content of tissues since other methodologies, such as the Dixon method, have proven accurate 
in this area, diseases that cause myelin degeneration, dysregulation of iron metabolism, and 
diseases featuring calcifications have been studied using QSM.  
 
Myelin sheaths cover the axons of nerves to insulate them from outside electrical currents. In 
diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS), 
demyelination of nerves in gray matter and the spinal cord is a clinical feature of the disease 
(186, 187). Cancer treatment with cranial radiation is also a common cause of demyelination of 
brain tissue, and has been shown to cause changes in normal-appearing white matter (188, 
189). Myelin is diamagnetic compared to water due to its high phospholipid content, and so 
susceptibility will increase as demyelination occurs. This increase in magnetic susceptibility has 
been observed in several studies using QSM (190, 191). 
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Iron-containing lesions, such as hemorrhage (see section 2.1.1) (192-194), cerebral 
microbleeds (184, 195, 196), traumatic brain injury (196, 197), and chronic MS lesions (190, 
191, 198, 199), have been the primary diagnostic targets of QSM to date. These lesions are 
highly paramagnetic compared to water, so they have improved the ability of clinicians to 
identify them and quantify disease progression. Deep gray matter also has very high iron 
content, so QSM improves the anatomic visualization of tissues within the basal ganglia 
(putamen, globus pallidus, and choroid plexus), thalamus, red nucleus, and dentate nucleus 
(184, 192, 200-203). 
 
Calcifications, often composed of hydroxyapatite (𝜒 = -14.83 ppm), are also prominent in 
various diseases (see section 2.1.2) (140, 204). QSM provides differentiation of calcific and 
hemorrhagic lesions in agreement with conventional SECT (45, 205, 206), and has improved 
the visualization of calcifications compared to methods utilizing background corrected phase 
images from T2*-weighted GRE (142) and susceptibility-weighted imaging sequences (207, 
208). To date, the ability of QSM to identify calcifications below 100 HU on SECT has not been 
studied. 
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Chapter 3 
3 Lesion Differentiation in Magnetic Resonance Imaging Phantoms 
 
3.1 Introduction 
The differentiation of intracranial calcifications and hemorrhage using imaging is of critical 
importance to patient diagnosis and care. In particular, low density lesions that fall below 100 
Hounsfield Units (HU) on conventional Single-Energy Computed Tomography (SECT) are of 
interest to researchers because the signal level of hemorrhage and low-density calcifications 
overlaps within this range. Multi-echo T2*-weighted GRE sequences are highly sensitive to 
hemorrhage, but the characterization is challenging because calcifications also appear as black 
spots due to their inherent magnetic susceptibility. Techniques that utilize the complex phase 
data from a GRE acquisition, known as Phase-Sensitive Magnetic Resonance Imaging (PS-
MRI) methods, have been utilized in clinical research studies to differentiate calcific and 
hemorrhagic lesions in vivo successfully. However, the in vivo studies currently available in the 
literature relied on a SECT threshold to determine if a lesion was calcific, which is not an 
adequate gold standard for low density lesions (45, 205, 206). To circumvent this issue, we 
have developed multiple agarose-based phantoms to use as a gold standard comparison for in 
vivo studies. 
 
Multiple studies in the literature have examined the use of parametric MRI for identifying calcific 
and hemorrhagic lesions on T2* maps. A study published in Radiology by Langkammer et al. 
demonstrated that R2*-mapping (R2* = 1/T2*) had a high correlation with iron content in the 
brains of human cadavers (209). They found that the iron concentration in gray matter tissues, 
including the globus pallidus, putamen, caudate nucleus, and thalamus, ranged from 49 to 205 
mg iron/kg of wet mass (209). These iron levels corresponded to T2* range of 13.8 to 33.3 ms 
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in these iron-laden normal tissues. In another study, 52 patients experiencing symptoms of 
Parkinson’s disease, brain iron—frequently elevated in these patients—was highly correlated 
with T2* parametric maps, and the T2* ranged from approximately 15 ms to 35 ms (210). 
Within cavernomas suspected of bleeds, the T2* was as low as approximately 7.7 ms (211). 
Roy et al. found that calcified neurocysticercosis lesions had a median T2* of 14.6 ms for 
lesions with a 120 kVp SECT attenuation of 142.10 HU (212). 
 
Based on these literature values, we qualitatively and quantitatively verified that the phantom 
materials generated the expected MR signal decay curves with minimal image artifacts and 
finally constructed several MR phantoms with calcific and hemorrhagic lesion models within 
biological constraints. 
 
3.2 Methods 
3.2.1 MRI Phantom Materials 
Many materials have been used in the literature to simulate calcific and hemorrhagic lesions. 
Based on the literature and prior experience making agarose-based phantoms (136), we chose 
to model calcification and hemorrhage using the materials listed in Table 3.1. 
Table 3.1: Phantom materials simulating calcific and hemorrhagic lesions 
Calcification Models Iron Models 
Hydroxyapatite (136, 213) Iron(III) Oxide (214) 
Calcium Chloride (215) Iron(II) Chloride (193) 
 Iron(III) Chloride (193, 211) 
 Iron Dextran (216, 217) 
 Hemoglobin (211) 
 
The materials, with the exception of hemoglobin, were suspended in 1% weight/volume 
agarose gel (#0710; Amresco, Solon, OH) within cylindrical, plastic 1.8ml cryovials ( #375418; 
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Thermo Scientific, Waltham, MA  ). The hydroxyapatite (#289396; Sigma-Aldrich, St. Louis, 
MO) and iron(III) oxide (#529311; Sigma-Aldrich) required emulsification in 0.01% Triton X 
(#112K09721; Sigma Aldrich) with a magnetic stir bar overnight. Following emulsification, the 
agarose was added, and the vials were agitated manually to ensure the uniform distribution of 
material (136). Hemoglobin was dissolved in sterile Lactated Ringer’s solution (#07-19-75-231; 
Baxter, Deerfield, IL) to reach physiologic concentrations.  
 
The phantom background material was comprised of LB Agar Miller (#1102830500; Millipore 
Sigma, Darmstadt, Germany) at a concentration of 3.7% weight/volume. This material provides 
physical strength, the flexibility to choose the orientation of the phantom relative to the main 
magnetic field and is reasonably tissue equivalent due to its protein and sodium chloride 
content. 
3.2.2 MRI Phantom Design 
There were several aspects of the MRI phantom design to be considered before construction of 
the phantom. First, a plastic container with a low magnetic susceptibility was required. Second, 
the vials had to be held parallel to each other within the background medium and be sufficiently 
far from the edges of the phantom to minimize the effect of signal loss at the air-phantom 
boundary. With these concerns in mind, two phantom designs were created. 
Preliminary Phantom Design 
The preliminary phantom design utilized a 12 cm x 12 cm test tube rack made of polypropylene  
for gel placement. Holes were drilled in the bottom of the test tube rack to enable removal of 
the vials. The tops of thirteen vials were wrapped in Parafilm M (P 7793; Sigma Aldrich, St. 
Louis, MO) and inserted into the test tube rack (Figure 3.1a). The agarose background was 
prepared and poured into a heat-safe polypropylene storage container with dimensions of 15.6 
cm x 15.6 cm x 8.6 cm (Ziploc Medium Square Container, SC Johnson, Racine, WI) and 
allowed to cool to a temperature of 50°C. The test tube rack was then inverted and placed in 
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the container so that the vials were immersed in the agarose. The phantom was then stored at 
4°C overnight to allow the agarose to set, and the test tube rack was removed, using a 
toothpick to release the vials from the test tube rack. Phantoms utilizing this design had 
abbreviations beginning with “P” to indicate the use of the preliminary design. 
 
 
Figure 3.1: Preliminary phantom design demonstrating the vial positioning in the test tube 
holder (a) and the completed preliminary phantom (b) with the agarose background. 
Round Phantom Design 
The preliminary phantom design allowed for a maximum of twelve samples and one control. 
Additionally, using an existing test tube holder did not allow for even spacing of the vials within 
the phantom or the ability to position all vials away from the phantom edge. Therefore, a 
second design was conceived to alleviate these problems. 
 
A 16-cm diameter, round, heat safe, polypropylene container (Large Bowl Food Storage 
Container, H-E-B, San Antonio, TX) was chosen for the phantom. The phantom was designed 
with a 2-cm buffer between individual samples. There was also greater than 2 cm between the 
outer ring of vials and the phantom edge to minimize signal loss from the air-phantom 
boundary. A total of nineteen samples fit within the container. A schematic of the phantom 
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design is shown in Figure 3.2. A custom test-phantom template to hold the vials in place was 
made from 1/8” craft plywood (Michaels, Irving, TX). Phantoms with this design were 
abbreviated “R” for round phantom. 
 
Figure 3.2: Schematic of the round phantom design. The cryovials measure 1 cm in 
diameter, and all vials were greater than 2 cm from the edge of the phantom and 2 cm 
away from all other vials. 
3.2.3 Material Validation Phantoms 
Hydroxyapatite and Iron (III) Oxide (P1 & P2) 
Several phantoms were made to validate the materials used in each phantom. The 
preliminary phantom design was used to create two phantoms that each contained six 
hydroxyapatite vials and six iron(III) oxide vials. The goal of these phantoms was to test calcific 
and hemorrhagic lesion models that had the same SECT HU value, as calculated using the 
equations presented in Nute et al. (135). Low HU samples were grouped in one phantom 
(Figure 3.3a) while high HU samples were placed in the second phantom (Figure 3.3b). The 
material concentrations for the desired SECT HU are shown in Table 3.2. 
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Figure 3.3: Iron oxide and hydroxyapatite phantoms a) P1, with low concentrations, and 
b) P2 with high concentrations of the two materials. The concentrations displayed here 
are in mg of analyte per mL. 
 
Table 3.2: Hydroxyapatite and Iron(III) Oxide sample specifications for both low and high 
concentrations. 
Phantom 
Predicted 
SECT (HU) 
Iron(III) Oxide 
Concentration 
(mg/mL) 
Hydroxyapatite 
Concentration 
(mg/mL) 
Low 
Concentration 
Phantom (P1) 
1 1.29 4.35 
5 2.24 6.94 
10 3.45 10.12 
15 4.55 13.37 
20 5.76 16.59 
35 10.47 23.02 
High 
Concentration 
Phantom (P2) 
40 12.75 29.37 
60 17.49 42.27 
70 19.80 48.71 
80 22.20 55.10 
100 24.43 67.96 
110 26.82 74.39 
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Hydroxyapatite and Iron Dextran (R1 & R2) 
A hydroxyapatite and iron dextran (INFeD; Allergan, Dublin, Ireland) phantom was made with 
the round phantom design, containing nine hydroxyapatite gels, nine iron dextran gels, and a 
vial of Milli-Q water (Millipore Sigma). A 2-mL vial of iron dextran (50 mg iron/mL) was scanned 
in air using SECT (HD750 CT; General Electric Healthcare, Waukesha, WI) to estimate the HU 
before making the dilutions. The concentrations of each material used in the phantom are given 
in Table 3.3. The SECT signal was approximately matched between the iron dextran and 
hydroxyapatite gels to test the feasibility of using the same concentrations of iron dextran for 
both CT and MRI lesion modeling. A schematic of the phantom is shown in Figure 3.4. 
 Table 3.3: Hydroxyapatite and Iron Dextran gel specifications and their estimated SECT 
attenuation in HU for the first iron dextran testing. This phantom had approximately 
matched SECT HU between the iron dextran and hydroxyapatite gels. 
Phantom 
Iron Dextran 
Concentration 
(mg iron/mL) 
Iron Dextran 
Estimated SECT 
HU 
Hydroxyapatite 
Concentration 
(mg/mL)  
Hydroxyapatite 
Estimated SECT 
HU 
Approximately-
Matched SECT 
HU (R1) 
0.59  5 13.22 20 
1.77  15 24.82 40 
3.54  30 42.24 70 
5.89  50 48.00 80 
8.25  70 59.53 100 
10.61  90 74.16  125 
11.79  100 117.61 200 
14.15  120 146.51 250 
32.41  255 194.24 350 
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Figure 3.4: Diagram of the phantom R1. Hydroxyapatite is shown in blue, iron dextran in 
red, and 1% w/v agarose in gold. The numbers refer to the concentration of material in 
each vial (iron dextran in units of mg Fe/mL, hydroxyapatite in mg/mL). 
Following the scanning of phantom R1, another hydroxyapatite and iron dextran phantom (R2) 
was developed which limited the iron concentration to avoid inducing chemical shift artifact 
(Table 3.4, Figure 3.5). As a result, the SECT attenuation was not matched between the calcific 
and hemorrhagic lesion models in phantom R2. 
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Table 3.4: Hydroxyapatite and Iron Dextran gel specifications for a second phantom. In 
this instance, SECT HU was not matched between the calcium and iron gels. 
Phantom Iron Dextran 
Concentration 
(mg iron/mL) 
Hydroxyapatite 
Concentration 
(mg/mL) 
Limited Iron 
Concentrations 
(R2) 
0.4 7.8 
0.8 15.7 
1.2 23.5 
1.6 31.4 
2 39.2 
2.4 58.8 
2.8 78.4 
3.2 137.3 
3.6 196.1 
 
 
Figure 3.5: Phantom R2 with adjusted iron dextran and hydroxyapatite concentrations. 
Iron dextran concentration values in the diagram are given in mg Fe/mL while 
hydroxyapatite concentrations are given in mg/mL. 
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Hydroxyapatite and Calcium Chloride (R3) 
Having a calcific substance that is soluble in water would improve the uniformity of the phantom 
materials and potentially enable the use of higher concentrations of calcium to model materials 
with more negative magnetic susceptibilities. A potential material was determined to be calcium 
chloride, which had been used to make alginate gel beads in another MRI phantom experiment 
(215). Serial dilutions of calcium chloride (CaCl2) in 1% w/v agarose (2.0, 1.0, 0.5, 0.25, 0.1, 
and 0.05 M) were prepared along with nine hydroxyapatite gels (13.2, 24.8, 42.2, 48.0, 59.5, 
74.2, 117.6, 146.5, and 194.2 mg/mL) and two iron dextran gels (1.77 and 5.89 mg iron/mL) for 
reference. This phantom will be abbreviated as R3. 
 
Iron(II) Chloride and Iron(III) Chloride (R4) 
The magnetic susceptibility of a compound depends primarily on the number of unpaired 
electrons present in the molecule (140, 204). While oxyhemoglobin has no unpaired electrons, 
deoxyhemoglobin has four unpaired electrons, and methemoglobin has five (204). The heme 
iron must be in the 2+ state to bind oxygen, at which point it is oxidized to the 3+ state (218, 
219). The goal of this phantom was to determine whether it was necessary to account for the 
iron valence state to model the hemorrhagic lesions seen clinically. A 10 mg iron/mL stock 
solution of FeCl2 (#50-901-14656; Fisher Scientific, Waltham, MA) was prepared in a 1% L-
ascorbic acid (#255564, Sigma Aldrich) buffer to ensure the iron remained in the 2+ valence 
state. The FeCl3 stock was also prepared to a concentration of 10 mg iron/mL in MilliQ water. 
1% agarose was added to dilute the solutions to the following concentrations: 0.0, 0.2, 0.4, 0.6, 
0.8, 1.0, 1.2, 1.4, and 1.6 mg iron/mL. The vials were then arranged according to the round 
phantom design  
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Figure 3.6: Phantom R4 arrangement of iron(III) and iron(II) chloride samples. Units are 
given in mg Fe/mL. 
Biological Calibration Phantom (RF1) 
 
Figure 3.7: Phantom RF1, a calibration phantom, featuring hydroxyapatite, iron dextran, 
hemoglobin, and iron(III) chloride. The numbers above the vials refer to the concentration 
in units of mg/mL for hydroxyapatite and mg Fe/mL otherwise. 
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The goal of this phantom was to provide calibration curves over a biological range of T2* 
values for calcifications and several iron-based compounds. Four vials each of hydroxyapatite, 
iron dextran, iron(III) chloride, and hemoglobin (in Lactated Ringer’s solution) were made to the 
specifications listed in Table 3.5. The vials were placed in the phantom as depicted in Figure 
3.7. The phantom abbreviation used was RF1 to indicate that it was one of the round finalized 
phantoms to be used in a future analysis (see Chapter 4). 
Table 3.5: Specifications for concentrations of hydroxyapatite, iron dextran, iron(III) 
chloride, and hemoglobin to be included in finalized calibration curves. Iron dextran 
concentration is given in mg iron/mL due to the lack of a nominal density for the dextran 
complex as a whole. Hemoglobin was assumed to be 0.31% iron per sample 
specifications. 
Hydroxyapatite 
(mg/mL) 
Iron Dextran 
(mg Fe/mL) 
Iron(III) Chloride 
(mg Fe/mL) 
Hemoglobin  
(mg Fe/mL) 
181.8 0.70 0.31 0.17 
210.3 1.40 0.62 0.34 
238.7 2.10 0.94 0.42 
267.4 2.80 1.25 0.66 
 
This phantom was scanned three times to test the repeatability of the MR results. 
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Biological Phantom with Mixed Materials (RF2) 
 
Figure 3.8: Diagram of the biological phantom with mixed materials. Lesion models with 
diagonal stripes represent mixtures while vials with smaller spots represent regions of 
differing material and concentration within a uniform background. 
A final phantom (RF2) with a variety of mixed lesions was created to assess the feasibility of 
identifying both mixtures of materials and smaller regions of differing susceptibility within a 
larger lesion. In total, eight mixtures were made with iron dextran and one other material—
hydroxyapatite, iron(III) chloride, or lyophilized human hemoglobin—evenly distributed 
throughout a 2% agarose background (Table 3.6). Eight additional lesion models were created 
with simulated regions of a different material or material concentration, hence referred to as 
“masses.” To manufacture the vials containing masses, several vials of hydroxyapatite and iron 
dextran (concentrations found in Table 3.6) were created with a 5% w/v agarose background to 
ensure structural integrity. Then a 5-mm Miltex standard biopsy punch (#3334; Integra 
LifeSciences, Plainsboro, NJ) was used to remove a cylindrical piece of the gel approximately 
3/8” deep. Agarose with the chosen background material was prepared at a concentration of 
2% w/v and the cylindrical mass was gently inserted into the vial with a metal spatula before 
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the agarose was set. A schematic of the vial placement within the phantom is provided in 
Figure 3.8. This phantom was scanned three times to test the repeatability of the MR results. 
Table 3.6: Agarose gel composition for a biological phantom with mixed materials. For the 
lesions with masses (“Mass”), Material 1 indicates the composition of the uniform 
background material while Material 2 indicates the concentration within the mass. 
Concentrations are reported in mg Fe/mL for iron containing compounds and mg/mL for 
hydroxyapatite 
Label Type Material 1  Material 1 
Concentration 
(mg Fe/mL 
OR mg/mL) 
Material 2  Material 2 
Concentration 
(mg Fe/mL 
OR mg/mL)  
HAP/ID 1 Mixture Hydroxyapatite 210.2 Iron Dextran 2.10 
HAP/ID 2 Mixture Hydroxyapatite 210.2 Iron Dextran 1.40 
HAP/ID 3 Mixture Hydroxyapatite 210.2 Iron Dextran 0.70 
IC/ID 1  Mixture Iron(III) Chloride 0.47 Iron Dextran 0.35 
IC/ID 2 Mixture Iron(III) Chloride 0.31 Iron Dextran 0.70 
IC/ID 3 Mixture Iron(III) Chloride 0.16 Iron Dextran 1.05 
Hb/ID 1 Mixture Hemoglobin 0.34 Iron Dextran 0.70 
Hb/ID 2 Mixture Hemoglobin 0.17 Iron Dextran 1.05 
ID/HAPm 1 Mass Iron Dextran 0.70 Hydroxyapatite 267.1 
ID/HAPm 2 Mass Iron Dextran 0.70 Hydroxyapatite 181.6 
ID/HAPm 3 Mass Iron Dextran 2.10 Hydroxyapatite 267.1 
ID/HAPm 4 Mass Iron Dextran 2.10 Hydroxyapatite 181.6 
IC/IDm  Mass Iron(III) Chloride 0.31 Iron Dextran 0.70 
ID/IDm 1 Mass Iron Dextran 1.40 Iron Dextran 0.70 
ID/IDm 2 Mass Iron Dextran 0.70 Iron Dextran 1.40 
ID/IDm 3 Mass Iron Dextran 0.70 Iron Dextran 2.80 
 
3.2.4 MRI Scan Protocol 
All phantom imaging was performed on a 3.0-T MRI system (MR 750, General Electric 
Healthcare) with an 8-channel head coil. The phantom was positioned with the vials parallel to 
B0 to minimize blooming. A three-dimensional (3D) T1-weighted ultrafast gradient echo with 
magnetization preparation (IR-FSPGR) was acquired to assess geometric accuracy near the 
vials. A T2*-weighted GRE was acquired for comparison of the signal level in the phantom to 
conventional clinical images. 3D susceptibility-weighted angiography (SWAN) sequence was 
acquired to examine the background phase—which is automatically reconstructed—in each 
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material (see Chapter 4). Finally, a 3D multi-echo fast gradient recalled echo (MFGRE) was 
acquired to assess signal changes with increasing echo time (TE) and calculate T2*, an 
inherent property of a material indicating the time required for signal dephasing caused by 
magnetic field inhomogeneity (for example, those caused by magnetic susceptibility) to occur. 
Protocol details are shown in Table 3.7. 
Table 3.7: MRI acquisition details for all phantom experiments, including repetition time 
(TR), inversion time (TI), receive bandwidth (BW), field-of-view (FOV), acquisition matrix 
Sequence IR-FSPGR  T2*-weighted GRE 3D SWAN 3D MFGRE 
# of Echo Times 1 1 6 12 
TE (ms) [min, max] 2.1 15 23.3a [4.7, 61.4] 
TR (ms) 5.7 600 37.6 65.2 
TI (ms) 400 - - - 
Flip Angle 20° 20° 15° 20° 
BW (kHz) 128 128 128 128 
FOV (mm) 220 220 220 220 
Phase FOV (% of FOV) 80 75 80 80 
Matrix 256 x 256 256 x 256 320 x 224 416 x 320 
Slice Thickness (mm) 1.4 5 1.4 1.4 
Scan Time 4:27 2:00 2:49 6:46 
a SWAN provides images that are a weighted average of the six echoes. The average TE is 
listed here. 
 
SECT was also acquired to determine the conventional CT attenuation level of the vials within 
the phantom and to ensure gel uniformity. All scanning was performed with our institution’s 
routine brain protocol. DECT was also acquired for phantoms with matched SECT HU 
(Hydroxyapatite and Iron Oxide phantoms and the first Hydroxyapatite and Iron Dextran 
phantom). Both protocols are listed in Table 3.8. The phantoms were placed in the head holder 
with the vials parallel to the z-axis of the scanner. 
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Table 3.8: Phantom experiment SECT and DECT protocols. 
Technique Parameter SECT DECT 
Scan Type Helical Helical (GSI-9) 
kVp 120 80/140 
mA 220 600 
Rotation Time (s) 0.8s 0.9 
Pitch 0.531 0.531 
CTDIvol (mGy) 65.2 132.6 
Image Thickness (mm) 0.625 0.625 
Interval (mm) 0.625 0.625 
Beam Width (mm) 20 20 
Scan FOV Head Head 
Display FOV (mm) 250 250 
 
3.2.5 Image Analysis 
In phantoms P1-2 and R1-4, circular regions of interest (ROIs) approximately 7.5 mm in 
diameter were placed within each vial on five consecutive images for the SECT, DECT (when 
acquired) calcium(water) and water(calcium), and each echo of the MFGRE. The mean of the 
voxels within each ROI was calculated; the standard deviation of the mean values (n = 5) was 
used to measure the dispersion across the five images. For phantom RF1, the calibration 
phantom, the mean and standard deviation of the signal over three acquisitions of the MFGRE 
were calculated. The T2* GRE was assessed qualitatively for signal suggestive of susceptibility 
lesions, where the signal decreases with increasing TE.  
 
For a multi-echo T2*-weighted GRE pulse sequence, the signal in a uniform material is 
expected to decay exponentially according to the following equation, 
 𝑆(𝑡) = 𝑆(𝑡 = 0) ∗ 𝑒−𝑇𝐸/𝑇2
∗
 Equation 3.1 
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where 𝑆(𝑡) represents the signal at time 𝑡. The mean MFGRE signal in each vial was fit to this 
equation using a non-linear least square fit in Matlab (R2016a; MathWorks, Natick, MA) to 
calculate the T2*. 
 
In phantom RF1, we tested reproducibility of the T2* calculations by performing the same 
analysis found above across three acquisitions of the MFGRE. We calculated the mean T2* 
and the standard deviation of the mean over the three acquisitions. In phantom RF2, voxel-
wise T2* calculations were made within the lesion models for one circular ROI (6.6 mm 
diameter, 34.2 mm2 area) placed by hand within the lesion models. When a given lesion 
contained a mass visible on the MRI, the ROI was placed at the z-location of the mass and 
included both the mass and a portion of the background material to mimic the placement of an 
ROI on a biological lesion with a mixed signal. The mean signal from each lesion was fit with 
both a monoexponential curve (Equation 3.1) and a biexponential curve (Equation 3.2) to 
characterize multiple materials within a single lesion model. 
 𝑆(𝑡) = 𝑎 ∗ 𝑒
−
𝑇𝐸
𝑇2∗1 + 𝑏 ∗ 𝑒
−
𝑇𝐸
𝑇2∗2 Equation 3.2 
The mean and standard deviation were calculated for each ROI on the T2* image. For lesions 
with masses that visibly contained regions of differing T2* values, a histogram was generated, 
and a kernel density estimator was applied in Matlab. The mean of each region was 
determined by finding the locations of the peaks in the kernel density estimate. The peak 
locations along the T2* axis of the histogram were compared to the values 𝑇2∗1 and 𝑇2
∗
2 from 
the biexponential fit of the mean signal in the ROI. 
3.3 Results 
3.3.1 Hydroxyapatite and Iron Oxide Preliminary Phantoms 
DECT water(calcium) and calcium(water) images were analyzed in both the low and high 
concentration phantoms. As the concentration of each material increased, the mean measured 
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calcium density increased for both materials (Figure 3.9), while the mean water value 
decreased for iron-based lesion models and increased for calcific lesion models. This result is 
in agreement with Nute et al. (135). 
 
Figure 3.9: DECT water/calcium decomposition measurements for iron oxide and 
hydroxyapatite samples with matched SECT HU. Calcium density increases as SECT HU 
increases for both materials. Note that the use of the calcium/water material 
decomposition does not indicate that calcium was present within the iron oxide samples 
(see Section 2.3.4). 
 
Figure 3.10: MFGRE magnitude images of the low concentration iron oxide (two bottom 
rows) and hydroxyapatite (two top rows) phantom for echo times of a) 4.5 ms, b) 14.5 ms, 
and c) 24.6 ms. At the highest echo time, the 10.47 mg/mL iron oxide sample (white arrow) 
becomes distorted. Note that very little signal is present in the iron oxide samples, even 
at low TE. Numeric labels represent the concentration of hydroxyapatite or iron oxide in 
units of mg/mL.  
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Low Concentration Phantom (P1) 
The iron oxide demonstrated very low signals on the MFGRE pulse sequence, even at low 
concentrations. The effect is demonstrated in Figure 3.10, where the six iron oxide mixtures are 
shown in the bottom two rows of the phantom for echoes 1, 3 and 5 (TEs of 4.5, 14.5, and 24.6 
ms). In Figure 3.10c, the shape of the vial containing the highest iron oxide concentration 
(10.47 mg/mL) is warped into that of a magnetic dipole (white arrow). At the same TEs, the 
hydroxyapatite vials show a slight decrease in the signal as echo time increases. In echoes 1 
and 3, there is almost no difference in the signal that can be visually appreciated between 
hydroxyapatite gels of different concentrations; by the fifth echo (Figure 3.10c), there begins to 
be visually lower signal in those vials with higher concentrations of hydroxyapatite.  
 
The quantitative analysis of the MFGRE signal showed that by a TE of approximately 30 ms, 
virtually all signal had dephased in the iron oxide samples. Three vials (4.55, 5.76, and 10.47 
mg/mL) had signal levels below 1000 AU at TE = 4.5 ms (Figure 3.11). The signal in each 
sample was normalized to the first echo to improve visualization of the concentration 
dependence, which can be noted for the three lowest concentration samples. T2* values were 
calculated for each vial (Table 3.9), but due to the extremely low signal values in three of the 
samples, the R2 of the exponential fit used to calculate the T2* was less than 0.2 and the 
values are therefore considered to be inaccurate. In general, we would expect the T2* to 
decrease with increasing iron presence in lesions with signal present above the noise floor.  
 
The hydroxyapatite samples did not decay to the noise floor and had a much higher initial 
signal than the iron oxide (Figure 3.12). For both materials, signal decayed steadily with 
increasing TE, and normalizing the signal demonstrates a concentration dependence in the 
decay rate. The T2* generally decreases with increasing analyte concentration (Table 3.9). The 
vials containing the three lowest concentrations of hydroxyapatite were positioned near the 
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edge of the phantom and were subject to increased signal decay due to proximity to the air-
phantom border, which may have impacted the T2* calculations. 
 
Figure 3.11: Iron oxide MFGRE signal at low concentrations. The signal in all samples 
dephased within a TE of 30 ms. Lower concentrations featured higher signal levels at 
lower TEs. The signal normalized to the first echo for each vial shows very little change 
in signal across the later echoes. The high normalized signal in the 10.47 mg/mL is solely 
indicative of the very low signal values across all echoes. 
 
Figure 3.12: Hydroxyapatite MFGRE signals for low concentrations. The signal decreased 
steadily with increasing echo time (TE), and higher concentrations generally had lower 
signal levels. The normalized signal shows that higher concentrations decay at a slightly 
faster rate with increasing TE than lower concentrations. 
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Table 3.9: T2* values for hydroxyapatite and iron oxide samples of varying concentrations. 
The mean signal over five images was used to calculate T2*. 
Hydroxyapatite 
Concentration 
(mg/mL) 
Calculated T2* (ms) Iron Oxide 
Concentration 
(mg/mL) 
Calculated T2* (ms) 
4.35 71.38 1.29 8.29 
6.94 63.50 2.24 4.54 
10.12 57.60 3.45 3.60 
13.37 71.39 4.55 ** 
16.59 63.15 5.76 ** 
23.02 48.90 10.47 ** 
**Curves were poorly fit by the monoexponential decay model, due to signal levels at the 
noise floor for all TEs. 
High Concentration Phantom (P1) 
A qualitative analysis of the MFGRE images for the high concentration phantom shows little to 
no signal in the iron-containing lesion models. However, there is a concentration dependence 
to the apparent size of the sample at a given TE. This effect is exaggerated as the TE is 
increased (Figure 3.13). The hydroxyapatite samples have similar signals regardless of 
concentration at low TE (Figure 3.13a), and the concentration dependence of the signal level 
becomes more obvious as TE increases (Figure 3.13c). There is no blooming artifact present in 
the vials containing hydroxyapatite. 
 
Figure 3.13: MFGRE magnitude images of the high concentration iron oxide (two upper 
rows) and hydroxyapatite (two lower rows) phantom with a) TE = 4.5 ms, b) TE = 14.5 ms, 
and c) TE = 24.6 ms. Numeric labels refer to the concentration of hydroxyapatite and iron 
oxide in each sample in units of mg/mL. Note the blooming in the iron oxide samples 
increases with TE and with increasing iron concentration. 
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Quantitative analysis of the MFGRE signal with TE shows that the hydroxyapatite samples in 
this phantom have a faster decay rate (lower T2*) than in the previous, lower concentration 
phantom, which is depicted graphically in the normalized signal plot of Figure 3.14. The 
concentration dependence of the signal decay is shown definitively in this phantom. The T2* 
parameter calculated in these hydroxyapatite samples ranged from 21.32 ms at a concentration 
of 189.70 mg/mL to 44.76 ms at 74.90 mg/mL (Table 3.10).  
 
The iron oxide signal levels within this phantom were all negligible, and no change was noted 
with TE (Figure 3.15). These signal levels were too low to provide an accurate assessment of 
the T2* for the samples.  
 
Figure 3.14: Hydroxyapatite signal in the high concentration preliminary phantom by 
echo time (TE). The normalized signal shows a clear concentration dependence in the 
decay rate of the signal with TE. 
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Figure 3.15: Iron oxide signal in the high concentration phantom shows a low signal at all 
echo times for all concentrations of iron oxide present. 
Table 3.10: T2* values for hydroxyapatite samples of varying concentrations. The mean 
signal over five images was used to calculate T2*. 
Hydroxyapatite 
Concentration 
(mg/mL) 
Calculated T2* (ms) 
74.9 44.76 
107.8 33.42 
124.2 32.00 
140.5 28.50 
173.3 22.78 
189.7 21.32 
 
3.3.2 Hydroxyapatite and Iron Dextran Phantoms 
Approximately Matched SECT HU Phantom (R1) 
The round phantom design minimized the signal loss caused by the air-phantom boundary by 
increasing the space between the samples and the outer edge of the phantom. The iron 
dextran tested in this phantom showed T1 shortening, indicated by the bright initial signal on 
the first echo of the MFGRE, and chemical shift artifact (black band above sample) at very high 
concentrations of iron dextran (Figure 3.16 a). Despite the high initial signal, the iron dextran 
displayed significant T2* decay, which was evident as the TE increased (Figure 3.16 b and c). 
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The hydroxyapatite samples were present in higher concentrations than in previous phantoms, 
and complete signal dropout was accomplished at later echoes (Figure 3.16 c). 
 
Figure 3.16: MFGRE magnitude images of an iron dextran (ID) and hydroxyapatite (HAP) 
phantom with the round design; sample concentrations are given in mg/mL for HAP and 
mg Fe/mL for ID. Iron dextran is on the top half and hydroxyapatite on the bottom half, as 
indicated by the white line in (a). The iron dextran displays T1 shortening (bright signal), 
and a chemical shift is present in high concentrations, indicated by the cyan circle (a). 
Signal remains present in several iron dextran samples at the third (b), and fifth (c) echoes 
and higher concentrations of hydroxyapatite were tested to decrease the T2* further 
relative to prior phantoms. 
Quantitatively, the iron dextran signal at the lowest TE varies, in large part due to the T1 effects 
seen in the phantom images. The highest concentration (32.41 mg Fe/mL) had complete signal 
dropout by a TE of 19.5 ms (Figure 3.17), but enough signal was present in the prior echoes to 
measure T2*. The relaxation rate is a function of the iron dextran concentration, with a T2* of 
86.92 ms at 0.59 mg Fe/mL down to 3.45 ms at 32.41 mg Fe/mL (Table 3.11). Notably, the 
hydroxyapatite samples had a similar range of T2* as the iron dextran (7.62 – 49.68 ms).  
 
DECT analysis was performed in this phantom to the iron- and calcium-based lesions because 
the SECT HU values were intentionally matched between the iron dextran and hydroxyapatite. 
Plotting the mean water(calcium) and calcium(water) values show that the materials are not 
separable using this material decomposition Figure 3.19. 
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Figure 3.17:  MFGRE signal changes with increasing echo time (TE) for iron dextran 
samples in a round phantom. Signal normalized to the first TE is displayed in the plot at 
the bottom to emphasize the concentration dependence of the signal decay. 
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Figure 3.18: MFGRE signal changes with increasing echo time (TE) for hydroxyapatite 
samples in a round phantom. Signal normalized to the first TE is displayed in the plot at 
the bottom to emphasize the concentration dependence of the signal decay. 
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Table 3.11: Calculated T2* for iron dextran and hydroxyapatite in a phantom with 
approximately matched SECT HU ranges. 
Iron Dextran 
Concentration 
(mg Fe/mL) 
SECT 
Attenuation 
(HU) 
Calculated 
T2* (ms) 
Hydroxyapatite 
Concentration  
(mg/mL) 
SECT 
Attenuation 
(HU) 
Calculated 
T2* (ms) 
0.59  8.72 86.92 13.22 22.85 49.68 
1.77  11.77 49.60 24.82 39.19 51.96 
3.54  19.33 29.58 42.24 66.65 29.91 
5.89  44.30 11.80 48.00 75.96 28.64 
8.25  67.49 7.36 59.53 87.05 24.50 
10.61  75.90 6.71 74.16  112.56 20.18 
11.79  78.23 6.68 117.61 178.84 12.58 
14.15  94.72 5.22 146.51 231.32 10.01 
32.41  218.53 3.45 194.24 326.78 7.62 
 
Figure 3.19: DECT calcium/water material decomposition data for iron dextran and 
hydroxyapatite samples. Note that sulfur is present in the iron dextran complex, which is 
not present amongst biological hemorrhage. 
Biological T2* Phantom (R2) 
This phantom demonstrated that iron dextran concentrations could be adjusted to create lesion 
models with biological levels of T2*. Lowering the concentration also had the added benefit of 
eliminating the chemical shift artifact that was seen in the vial with the most dextran complex in 
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the previous phantom (Figure 3.16). The ranges of the calculated T2* for the iron dextran and 
hydroxyapatite lesions, respectively, were found to be 30.44 – 89.49 ms and 5.53 – 42.22 ms 
(Table 2.2, Figure 3.20, Figure 3.21). The T2* values for hemorrhagic lesion models are in 
agreement with the literature values for iron-laden gray matter (4.1 – 62.5 ms) (209) and 
cavernomas (211), while the hydroxyapatite samples covered nearly the full range of T2* (9 – 
50 ms) found in calcifications by Roy et al. (212). 
Table 3.12: Calculated T2* from the monoexponential fits for various concentrations of 
iron dextran and hydroxyapatite in a phantom with biological susceptibility levels. 
Iron Dextran 
Concentration 
(mg iron/mL) 
Calculated  
T2* (ms) 
Hydroxyapatite 
Concentration 
(mg/mL) 
Calculated  
T2* (ms) 
0.4 89.49 7.8 42.22 
0.8 80.85 15.7 23.81 
1.2 63.82 23.5 17.52 
1.6 49.26 31.4 13.01 
2 45.48 39.2 10.00 
2.4 42.03 58.8 8.94 
2.8 37.96 78.4 7.56 
3.2 33.60 137.3 6.83 
3.6 30.44 196.1 5.53 
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Figure 3.20: MFGRE signal and normalized signal for hydroxyapatite with biological T2* 
levels. The T2* ranges from 5.53 to 42.22 ms in this phantom. 
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Figure 3.21: MFGRE signal and normalized signal for iron dextran with T2* values within 
the range expected in normal gray and white matter. The T2* in this phantom ranges from 
30.44 to 89.49 ms. 
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3.3.3 Calcium Chloride Phantom (R3) 
The MFGRE signal decay curves for the serial dilutions of calcium chloride in this phantom 
experiment are shown in the figure below (Figure 3.23). Low T2* is indicative of faster signal 
dephasing due to magnetic field inhomogeneities. Overall, hydroxyapatite had a lower T2* to 
SECT attenuation ratio (Figure 3.22), making it more similar to calcification than the calcium 
chloride. 
 
 
Figure 3.22: Calculated T2* versus the SECT attenuation of the hydroxyapatite and 
calcium chloride gels. The T2* of the calcium chloride is higher than that of the 
hydroxyapatite for all SECT levels investigated. 
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Figure 3.23: MFGRE magnitude signal for various concentrations of calcium chloride with 
and without signal normalization 
 65 
 
3.3.4 Iron Oxidation State Phantom (R4) 
The 0.4 mg Fe/mL concentration of iron(II) chloride was excluded from analysis due to the 
presence of an air bubble. Qualitatively, the signal of the iron(II) chloride was generally higher 
than that of the iron(III) chloride for the same amount of iron present. The signal of each 
material was concentration dependent, but the decrease in the normalized signal was greater 
for iron(III) than iron(II) (Figure 3.24, Figure 3.25). 
 
The iron oxidation state of iron was shown to change the calculated T2* relaxation time for 
equal concentrations of iron particles. The ranges of calculated T2* for iron(II) chloride and 
iron(III) chloride were 84.96 – 777.14 ms and 4.01 – 90.53 ms, respectively. Both compounds 
demonstrated monotonically decreasing T2* with increasing iron concentration.  
Table 3.13: Calculated T2* for various concentrations of iron(II) chloride and iron(III) 
chloride in a phantom. The 0.4 mg Fe/mL iron(II) chloride sample was excluded due to the 
presence of an air bubble. 
Iron (II) Chloride 
Concentration 
(mg Fe/mL) 
Calculated  
T2* (ms) 
Iron(III) Chloride 
Concentration 
(mg Fe/mL) 
Calculated  
T2* (ms) 
0.2 777.14 0.2 90.53 
0.4 -  0.4 30.11 
0.6 190.31 0.6 15.63 
0.8 133.91 0.8 10.57 
1.0 117.55 1.0 7.31 
1.2 105.89 1.2 5.67 
1.4 101.34 1.4 4.87 
1.6 84.96 1.6 4.01 
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Figure 3.24: Iron(II) Chloride MFGRE signal data. Units of concentration are given in mg 
Fe/mL. Note that while there is a concentration dependence in the normalized plot, there 
is relatively little signal dropout even at high concentrations. 
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Figure 3.25: Iron(III) chloride MFGRE signal curves. Units of concentration are given in mg 
Fe/mL. There is a large signal dropout at high iron concentrations that are not seen when 
the iron is in the 2+ oxidation state. 
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3.3.5 Final Biological Phantoms 
Calibration Phantom (RF1) 
Multiple materials were made to span the clinical range of expected T2* values in patients. Of 
the iron containing lesion models, hemoglobin had the highest T2*, followed by iron dextran 
and iron(III) chloride (Table 3.14). This range is highly desirable in a single phantom because 
there may be multiple categories of hemorrhage (acute, subacute, chronic, etc.) imaged within 
a clinical trial. The standard deviation of the T2* calculated from three different MFGRE 
acquisitions was very low (0.02 – 0.45 ms), indicating good repeatability. The normalized signal 
curves for each material are found in Figure 3.26 a-d. 
 
Table 3.14: Mean ± standard deviation of the T2* calculated for three acquisitions of the 
MFGRE.  
Hydroxy-
apatite 
Conc. 
(mg/mL) 
181.8 210.3 238.7 267.4 
T2* (ms) 8.74 ± 0.03 7.66 ± 0.08 7.07 ± 0.10 6.40 ± 0.22 
Iron Dextran 
Conc.  
(mg Fe/mL) 
0.7 1.4 2.1 2.8 
T2* (ms) 57.85 ± 0.15 44.28 ± 0.06 35.96 ± 0.06 30.87 ± 0.02 
Iron(III) 
Chloride 
Conc.  
(mg Fe/mL) 
0.31 0.62 0.94 1.25 
T2* (ms) 12.04 ± 0.02 5.09 ± 0.04 3.39 ± 0.04 3.11 ± 0.12 
Hemoglobin 
Conc. 
(mg Fe/mL) 
0.17 0.34 0.42 0.66 
T2* (ms) 128.98 ± 0.45 75.85 ± 0.24 74.21 ± 0.17 16.13 ± 0.04 
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Figure 3.26: Normalized MFGRE signal curves for a) hydroxyapatite, b) iron(III) chloride), 
c) iron dextran, and d) human hemoglobin. 
Biological Phantom with Mixed Materials (RF2) 
Voxel-wise T2* fitting of ROIs within each sample returned T2* values between 3.92 ms and 
80.86 ms. The mean and standard deviation of the T2* for each mixture is located in Table 
3.15. Displaying the ROIs in a single plane (Figure 3.27) demonstrates the presence of the 
hydroxyapatite lesions (upper left) within four samples of iron dextran. The mixtures did not 
display large non-uniformities, and the standard deviations in the T2* measurements were 
small. 
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Figure 3.27: Voxel-wise T2* calculations for each sample displayed in the same plane 
along the z-axis. The four vials labeled ID/HAPm have an iron dextran background and 
hydroxyapatite masses, and additional analysis was performed for these samples. 
 
Figure 3.28: An example of the histogram analysis for the iron dextran samples that 
contained hydroxyapatite masses. A kernel density estimate (black line) was fit to the data 
to estimate the mean T2* of the background and mass. This suggests that voxel-wise 
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histogram analysis of T2* might contain characterizing information that could be used 
clinically. 
Table 3.15: Mean and standard deviation of each mixture or sample without visible mass 
for the voxel-wise calculation of T2*. 
Lesion Model Mean T2* (ms) Standard Deviation (ms) 
HAP/ID 1 10.00 1.41 
HAP/ID 2 7.58 0.44 
HAP/ID 3 11.69 0.84 
IC/ID 1 6.14 0.28 
IC/ID 2 8.58 0.38 
IC/ID 3 18.51 0.72 
Hb/ID 1 48.54 2.38 
Hb/ID 2 29.01 1.10 
IC/IDm 9.46 1.06 
ID/IDm 1 48.04 3.11 
ID/IDm 2 48.54 2.38 
ID/IDm 3 45.22 4.01 
 
Table 3.16: T2* estimates for lesions containing masses, resulting from the biexponential 
fit of the ROI means and the peak location of the T2* kernel density estimate for the voxel-
wise calculations. 
Lesion 
Model 
Biexponential Fit 
Kernel Density 
Estimate 
Biexponential Fit Error 
𝑻𝟐∗𝟏 
(ms) 
𝑻𝟐∗𝟐 
(ms) 
Peak 1 
(ms) 
Peak 2 
(ms) 
𝑻𝟐∗𝟏 Err.  
(ms [%]) 
𝑻𝟐∗𝟐 Err.  
(ms [%]) 
ID/HAPm 1 3.58 34.17 8.38 39.33 -4.80 [-57%] -5.16 [-13%] 
ID/HAPm 2 7.87 47.26 10.75 48.45 -2.88 [-27%] -1.19 [-2.5%] 
ID/HAPm 3 7.09 62.21 8.91 59.46 -1.82 [-20%] 2.75 [4.6%] 
ID/HAPm 4 10.74 89.72 9.34 52.86 1.40 [15%] 36.86 [70%] 
 
For the four lesion models with masses that were apparent on the T2* map (ID/HAPm 1-4, 
Figure 3.27), the results of the biexponential fitting and kernel density estimate (example in 
Figure 3.28) are displayed in Table 3.16. The estimates from the biexponential fit were within 
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approximately 5 ms of the T2* calculated from the peaks of the histogram’s kernel density 
estimate. Overall, a linear fit of the estimated T2* values from the biexponential fit versus the 
peak locations of the voxelized T2* calculations had an R2 value of 0.849, indicating that the 
two analysis methods were correlated (Figure 3.29). The biexponential fit of the higher T2* 
peak from the iron background did not fit well, and there was a 70% overestimate of the T2*. 
However, the mass was angled so that there was very little background in the ROI, and the 
higher peak was not evident in the histogram. 
 
Figure 3.29: A linear fit of the T2* estimates resulting from the voxelized (kernel density) 
and ROI-based (biexponential fit) T2* estimates for iron dextran lesions with 
hydroxyapatite masses demonstrates correlation between the two analysis methods. 
3.4 Discussion 
The goal of this study was to validate materials for an MRI phantom of calcific and hemorrhagic 
lesion models and construct a final phantom with T2* properties within biological constraints. 
We determined that separate phantoms were required for DECT and PS-MRI. We analyzed 
two calcium-containing compounds—hydroxyapatite and calcium chloride—and five iron 
compounds, including iron(III) oxide, iron dextran, iron(II) chloride, iron(III) chloride, and human 
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hemoglobin. Out of these materials, the final MRI phantom was made from hydroxyapatite, iron 
dextran, iron(III) chloride, and hemoglobin. 
 
One of the original goals of this work was to find a compound that could be used for both an 
MRI phantom and DECT phantom at the same concentrations. This goal was not met because 
that MRI is significantly more sensitive to the presence of paramagnetic materials such as iron 
than is CT. Concentrations of iron oxide high enough to mimic the appearance of hemorrhage 
on SECT and DECT (utilized by Nute et al. (135)) induced significant artifacts on T2*-weighted 
pulse sequences, and demonstrated virtually no signal at the TEs examined. Since iron oxide is 
not soluble in water, it would have been difficult to lower the concentration further compared to 
what was used in the lower concentration phantom. Therefore, iron oxide was eliminated as a 
possibility for modeling hemorrhagic lesions on MRI. 
 
Since one of the primary drawbacks of using iron oxide in an MR phantom was insolubility in 
water, we focused on utilizing iron compounds that were easily dissolved is water. While many 
studies have used superparamagnetic iron oxide nanoparticles, as found in ferumoxytol 
(Fereheme; AMAG Pharmaceuticals, Waltham, MA), these would feature a very high magnetic 
susceptibility for a given iron concentration, and thus were ruled out. Instead, we chose to use 
iron dextran, another compound, like ferumoxytol, that is used to treat anemia intravenously. 
Iron dextran is soluble in water, and at appropriate concentrations (0.4 – 5.6 mg Fe/mL), was 
shown to have T2* values consistent with the literature for pathologically iron-laden tissues. It 
should be noted that this compound did shorten T1, so care must be taken to use this in 
phantoms appropriately since it will not adequately simulate the T1 properties of hemorrhage. 
 
Iron chlorides were yet another option for an MR hemorrhage model. Iron exists in both the 2+ 
and 3+ oxidation states in the body (218, 219), and hematomas exhibit different T2* properties 
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as the lesion progresses from acute to chronic states and the density and oxidation states 
change (3, 26, 220). Chronic hemorrhage, heavy in the iron storage proteins hemosiderin and 
ferritin, and most forms of hemoglobin primarily contains iron in the more stable 3+ oxidation 
state (218, 219). Since Fe2+ can bind oxygen, it is primarily located in deoxyhemoglobin in 
patients with normal iron metabolism; however, when Fe2+ is found outside in tissues, it can 
induce tissue damaging free radical formation (220-222). This potential for iron-related damage 
to normal brain tissue due to disordered iron metabolism may be a factor in certain neurological 
diseases such as Parkinson’s disease (221-223). However, due to the possibility that we may 
see more than one stage of hemorrhage or iron deposition due to multiple etiologies, we 
investigated the use of both iron(II) and iron(III) chloride in phantoms. We found that iron(II) 
chloride had a much higher T2* at similar iron concentrations compared to iron(III) chloride. 
Studies in the literature indicate that at a magnetic field strength of 3.0 T, the T2* of normal 
tissues ranged from 13.8 to 45.5 ms in seven male cadavers (age 38-81 years, mean age 52.3 
years) (209, 224). In comparison to those biological values, the lowest T2* found in the iron(II) 
chloride samples was 84.96 ms. Therefore, we excluded iron(II) chloride from subsequent 
phantoms and analysis. 
 
Iron dextran was investigated for potential use as a DECT phantom material, but we found that 
adequate separation of the hydroxyapatite and iron dextran was not possible using the 
methods developed by Nute et al. (135). Iron oxyhydroxide, which contains sulfur, is the 
primary iron-containing compound in iron dextran (225). The addition of sulfur increases the 
attenuation due to photoelectric effect compared to the iron-containing compounds found in the 
body (226). Despite the lack of translation of an iron compound from CT to MRI phantoms, 
hydroxyapatite—also utilized by Nute et al.—was the material selected to model calcific lesions 
over calcium chloride. Calcium chloride did not demonstrate a T2* value comparable to clinical 
studies for a given SECT HU (212). Hydroxyapatite does have limitations, however. The 
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material is not soluble in water, and therefore must be carefully emulsified, typically overnight, 
and manually shaken to achieve uniformity in agarose gels. While a magnetic stir bar was used 
to aid the emulsification process, adequate emulsification was not possible when 
concentrations exceeded approximately 275 mg/mL.  
 
The final phantoms utilized for the study were comprised of hydroxyapatite, iron dextran, 
iron(III) chloride, and lyophilized human hemoglobin (as a biological reference). The MFGRE 
and SWAN data acquired for these two phantoms will be used in a future analysis (see Chapter 
4). The calibration phantom will allow for direct comparisons of iron and calcium content in 
human tissue based on comparisons of the T2* and eventually magnetic susceptibility (See 
Chapter 4 for an evaluation of phase-sensitive MR techniques in these phantoms). The second 
of these biological phantoms features mixed lesions with various combinations of iron and 
calcium compounds as well as vials containing masses of other materials within a uniform 
background containing iron. It is particularly important to assess how well susceptibility 
mapping maintains lesion sizes in the presence of high susceptibility lesions, and we plan on 
testing this in phantom RF2. We showed in this chapter that lesions with masses featuring two 
dramatically different T2* values are best modeled using a voxel-wise analysis of the relaxation 
parameters. However, a biexponential fit of the mean signal across TEs provides a better fit 
than a monoexponential, and can potentially be used to estimate the two T2* values to within 
approximately 5 ms. Using this additional analysis may be useful to determine whether lesions 
in patients may contain more than one compound or density. 
 
In making the final phantoms (Phantoms RF1 and RF2), there were several limitations. 
Hemoglobin is soluble in water to 20 mg/mL, but to adequately match the concentrations found 
in human blood, higher concentrations were necessary. Therefore, hemoglobin was the only 
material dissolved in Lactated Ringer’s solution, which increased the solubility to over 200 
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mg/mL. There may be slight differences in the T2* calculations caused by changing the 
background material from agarose, which itself modifies T2 proportionally with its viscosity 
(227, 228). In the final phantom with mixed lesions, the concentration of the background 
agarose was raised to 2% weight/volume to keep the material in the masses, particularly the 
iron compounds, from bleeding into the surrounding agar background. However, this caused 
the agarose to solidify quickly, and several of the masses were mispositioned in the vials and 
could not be adequately imaged. The masses of the most interest, the calcific masses 
surrounded by iron dextran, were all readily visible, and so forming new samples and 
rescanning was deemed unnecessary. 
 
We also limited the data used in the T2* calculations for all but the final phantom to the mean 
over five images per vial. The T2* calculations in the final phantom were based on calculations 
for each voxel within an ROI. While this voxelized T2* mapping is possible and provides 
additional information about the spatial variation in T2*, since the majority of the phantoms 
were meant to validate the general MR properties of the materials with a simple methodology, 
we did not undertake this more computationally intensive analysis in every phantom at this 
point. 
  
 77 
 
Chapter 4 
4 Magnetic Resonance Imaging Acquisition and Processing 
  
4.1 Introduction 
As discussed in Section 2.5, T2*-weighted Gradient Recalled Echo (GRE) pulse sequences are 
highly sensitive to changes in the magnetic susceptibility of tissues. It is the most commonly 
utilized sequence in the clinic for identifying chronic intracranial bleeds, cerebral microbleeds, 
and iron deposits. These lesions appear as black spots, representative of signal loss, and are 
known as “foci of susceptibility.” However, the specificity of this image type is limited since 
calcific lesions appear identical to hemorrhage due to their low proton density and diamagnetic 
characteristics.  
 
The goal of this study was to utilize the phantoms developed in Chapter 3 to determine which 
pulse sequences and post processing algorithms provided the highest specificity for 
distinguishing calcification and hemorrhage. The methods investigated for this purpose include 
susceptibility weighted angiography (SWAN) sequence filtered phase images, background 
subtracted phase images from Projection onto Dipole Fields (PDF), and quantitative 
susceptibility mapping (QSM). 
 
4.2 Methods 
4.2.1 Phantoms 
The phantoms used for this study included phantoms RF1 and RF2 from Chapter 3.3.5. 
Phantom RF1 provided calibration data for hydroxyapatite, iron dextran, iron(III) chloride, and 
hemoglobin at various concentrations (Table 3.5). Phantom RF2 focused on mixtures of the 
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materials present in RF1 as well as testing the feasibility of differentiating small calcific masses 
from hemorrhage models (Table 3.6). 
4.2.2 MRI Scan Prototcol 
All phantom imaging was performed on a 3.0-T MRI system (MR 750, General Electric 
Healthcare) with an 8-channel head coil. The phantoms were positioned with the vials parallel 
to B0 to minimize blooming. A three-dimensional (3D) T1-weighted ultrafast gradient echo with 
magnetization preparation (IR-FSPGR) was acquired to assess geometric accuracy near the 
vials. 3D susceptibility-weighted angiography (SWAN) sequence was acquired to examine the 
background phase—which is automatically reconstructed—in each material, and we acquired a 
3D multi-echo fast gradient recalled echo (MFGRE) for generating both background-subtracted 
phase imaging with PDF and susceptibility distributions from QSM. Protocol details are in Table 
4.1. The SWAN and MFGRE sequences were each acquired three times to check the 
repeatability of the test metrics. 
Table 4.1: MRI acquisition details for all phantom experiments, including repetition time 
(TR), inversion time (TI), receive bandwidth (BW), field-of-view (FOV), acquisition matrix 
Sequence IR-FSPGR  3D SWAN 3D MFGRE 
# of Echo Times 1 6 12 
TE (ms) [min, max] 2.1 23.3a [4.7, 61.4] 
TR (ms) 5.7 37.6 65.2 
TI (ms) 400 - - 
Flip Angle 20° 15° 20° 
BW (kHz) 128 128 128 
FOV (mm) 220 220 220 
Phase FOV (% of FOV) 80 80 80 
Matrix 256 x 256 320 x 224 416 x 320 
Slice Thickness (mm) 1.4 1.4 1.4 
Scan Time 4:27 2:49 6:46 
a SWAN provides images that are a weighted average of the six echoes. The average TE is 
listed here. 
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4.2.3 Phase-Sensitive MR Post-Processing 
Post-processing of the SWAN sequence was performed at the scanner by selecting the option 
to reconstruct a high-pass filtered phase image from the k-space data. Real, imaginary, and 
magnitude images were generated for all echoes of the MFGRE pulse sequence at the 
scanner; additional processing for the MFGRE was performed on an external workstation (2.8 
GHz Dual-Core Opteron Processor 8220 (Advanced Micro Devices, Santa Clara, CA) with up 
to 128 GB of RAM). The phase data was calculated from the real and imaginary images; a 
temporal phase unwrapping algorithm developed by Kressler et al. was used to calculate a 
map of the measured magnetic field (180, 183). Aliased frequencies in the magnetic field map 
were removed using the method described by Liu et al. (183). The final background-removed 
phase image was calculated using the Projection onto Dipole Fields (PDF) method (154), which 
eliminated phase shifts caused by non-local susceptibility effects (i.e., the air-phantom 
boundary). The resulting field map from the PDF was used as an input to morphology-enabled 
dipole inversion (MEDI) QSM processing (167, 182), which returned a map of the magnetic 
susceptibility within the phantom in units of parts per billion (ppb). 
4.2.4 Image Analysis 
Phantom RF1 
For each acquisition, regions-of-interest (ROIs) were defined for each vial on five consecutive 
images to create larger volumes-of-interest (VOIs). The same VOIs were applied to the SWAN 
filtered phase images, the PDF results, and the QSM images. The mean of each VOI was then 
calculated for a given acquisition. The standard deviation of the VOI mean over three 
acquisitions was calculated for each sample and image type. Calibration curves for each image 
type and material were defined by linear regression of the signal versus material concentration 
(in mg/mL for hydroxyapatite and mg Fe/mL for iron-containing samples). 
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Phantom RF2 
In phantom RF2, VOIs were defined spanning five consecutive images within each sample. 
The mean and standard deviation in the VOI across the three acquisitions were calculated. By 
plugging the known composition of each lesion model into the QSM calibration curves and 
taking the sum of the two material susceptibilities, we determined whether the expected 
susceptibilities were additive. The percent error was calculated relative to the predicted value. 
The diameter of a hydroxyapatite masse located within a hemorrhagic model (ID/HAPm 1) was 
measured on both the IR-FSPGR and QSM images to determine the geometric accuracy of the 
QSM images. The measurements were made by placing a line profile across the widest portion 
of the hydroxyapatite mass in five consecutive images. The diameter was calculated using the 
full width half max (FWHM) of the mass for both image types. The percent error was calculated 
relative to the IR-FSPGR, which has better geometric accuracy than the MFGRE pulse 
sequence that the QSM is based on. 
4.2.5 Statistical Analysis 
In phantom RF1, the mean values of the defined VOI for each acquisition were grouped into 
categories of hemorrhagic or calcific lesion models. Receiver operating characteristic (ROC) 
analysis was performed to determine the optimal threshold between the diamagnetic 
hydroxyapatite samples and the paramagnetic iron samples. The diameters of the 
hydroxyapatite mass as measured on the IR-FSPGR and QSM sequences were compared 
using a two-sided Student’s t test with α = 0.05.  
4.3 Results 
4.3.1 Phantom RF1 Analysis 
The mean and standard deviation within each sample is reported in Table 4.2. In the 
hydroxyapatite samples, linear fits of the SWAN filtered phase, PDF, and QSM had negative 
slopes with hydroxyapatite concentration (Figure 4.1). While the SWAN phase demonstrated a 
negative trend with increasing hydroxyapatite content, the R2 was only 0.437, and the phase 
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does not decrease monotonically. For linear fits of the same VOIs on PDF and QSM images, 
the R2 values were 0.927 and 0.830, respectively, which indicated a tighter relationship with 
concentration than for the SWAN filtered phase images. In the iron-containing samples, SWAN 
filtered phase images also demonstrated poor fits with iron concentration for all three materials 
tested (Figure 4.2). The slope of the fit for hemoglobin was also negative while the fits for iron 
dextran and iron(III) chloride were positive, making it difficult to distinguish between potentially 
diamagnetic and paramagnetic materials (Figure 4.2a). In the iron-containing samples, PDF 
and QSM both had better fits overall than the SWAN phase images. However, QSM processing 
had a much tighter fit for the iron(III) chloride samples (R2 = 0.972) than PDF did (R2 = 0.367). 
This difference may be attributable to the spherical mean value (SMV) processing used within 
the QSM algorithm that is not used on the final PDF image. SMV computes the mean of a 
sphere several voxels in diameter for all voxels within the image, which effectively eliminates 
outlier voxels within uniform regions of the phantom (229). 
 
Figure 4.1: SWAN filtered phase (in mrad), PDF (in mrad), and QSM (in ppb) means for the 
hydroxyapatite samples. Error bars represent the standard deviation in the mean value 
across three acquisitions. 
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Table 4.2: Mean and standard deviation in phantom RF1 for the SWAN filtered phase, PDF, 
and QSM images. Concentration for hydroxyapatite is given in untis of mg/mL while iron-
containing compounds are reported in mg Fe/mL. Values marked by an asterisk have high 
variability between acquisitions and correspond with the samples with the highest 
magnetic susceptibility in the phantom.  
Compound 
Concentration 
(mg Fe/mL or 
mg/mL**) 
SWAN Filtered 
Phase (rad) 
PDF (ppb) QSM (ppb) 
H
e
m
o
g
lo
b
in
 
0.17 82.1 ± 3.9 174.6 ± 0.6 232.3 ± 5.4 
0.34 -63.3 ±4.2 307.5 ± 1.1 436.6 ± 7.0 
0.42 168.9 ± 19.6 366.9 ± 1.0 461.5 ± 7.3 
0.53 -304.4 ± 16.8 695.2 ± 0.9 643.5 ± 5.7 
Ir
o
n
 D
e
x
tr
a
n
 
0.70 7.6 ± 0.7 628.9 ± 1.4 738.4 ± 1.6 
1.40 -54.0 ± 4.0 1215.3 ± 3.8 1349.4 ± 8.5 
2.10 68.2 ± 4.9 1829.4 ± 2.4 2071.5 ± 14.0 
2.80 5.0 ± 8.2 2414.6 ± 4.9 2536.1 ± 31.3 
Ir
o
n
(I
II
) 
C
h
lo
ri
d
e
 0.31 35.3 ± 2.3 1007.4 ± 2.9 862.9 ± 5.5 
0.62 -21.6 ± 19.4 2475.2 ± 20.9 2072.4 ± 24.9 
0.94 11.0 ± 75.7 1675.2 ± 9464.3* 837.2 ± 3054.8** 
1.25 53.2 ± 1.8 3501.2 ± 920.6* 3363.8 ± 407.4** 
H
y
d
ro
x
y
-
a
p
a
ti
te
**
 181.8 -15.9 ± 26.3 -216.9 ± 1.9 -167.7 ± 4.7 
210.3 168.7 ± 38.4 -223.6 ± 3.3 -157.1 ± 10.3 
238.8 -397.7 ± 19.9 -290.0 ± 7.6 -210.6 ± 12.8 
267.4 -256.7 ± 9.3 -334.9 ± 40.0 -250.6 ± 7.5 
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Figure 4.2: Hemoglobin, iron dextran, and iron(III) chloride signal on a) SWAN filtered 
phase, b) PDF, and c) QSM images versus iron concentration. The error bars represent 
the standard deviation of a VOI measurement across three acquisitions. Note that the 
mean and standard deviation in an iron(III) chloride samples with the highest iron 
concentration each excluded an extreme outlier in both the PDF and QSM fits (see Figure 
4.3). 
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Figure 4.3: Images of phantom RF1 demonstrate the impact of poor phase unwrapping in 
the PDF and QSM processing for an iron(III) chloride sample (yellow circles). The 
acquisition shown in the top row shows a primarily positive phase on PDF (a) with some 
residual phase wraps, but a positive QSM proportional with its iron concentration (b). The 
bottom row is another acquisition in the same scan session where the phase has a 2π 
shift in the PDF (c), and thus the estimated susceptibility was negative (d). 
4.3.2 Phantom RF2 Analysis 
The predicted susceptibility for each mixture within the phantom is given in Table 4.3. The 
percent errors relative to the predicted value were very high for all material combinations 
except that of iron(III) chloride and iron dextran, which had a maximum error of 20.4%. 
Therefore, we have experimentally verified that susceptibility is not an additive quantity in these 
lesion types in most cases. 
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Table 4.3: Predicted susceptibility based on the mixture concentrations in phantom RF2 
input into the calibration curves for QSM defined in Phantom RF1. These values were 
compared to the measured susceptibility in the mixtures, and the percent error was 
calculated 
Label Predicted 
Susceptibility 
Measured Susceptibility 
(ppb) 
Percent Error (%) 
HAP/ID 1 1798.0 870.1 ± 0.5 -51.6 ± 0.1 
HAP/ID 2 1186.5 806.3 ± 45.2 -32.0 ± 3.8 
HAP/ID 3 575.0 276.3 ± 46.2 -51.9 ± 8.0 
IC/ID 1  1877.7 1897.6 ± 47.4 1.1 ± 0.2 
IC/ID 2 1771.7 1634.4 ± 49.9 -7.7 ± 0.1 
IC/ID 3 1691.3 1345.9 ± 3.2 -20.4 ± 0.4 
Hb/ID 1 1172.5 697.5 ± 0.8 -40.5 ± 2.5 
Hb/ID 2 1290.8 858.3 ± 5.7 -33.5 ± 2.8 
 
The diameter of a hydroxyapatite lesion was assessed using FWHM measurements on the IR-
FSPGR and QSM image sets. The mean diameter (± one standard deviation) was 5.04 ± 0.11 
mm on the IR-FSPGR and 3.14 ± 0.13 mm on the QSM. The measured diameter on QSM was 
1.90 mm (95% confidence interval: [1.79,2.02]), and the difference was statistically significant, 
with a p-value < 0.001. 
4.3.3 Statistical Analysis 
Histograms of the individual VOI means for all iron-containing samples (red), and 
hydroxyapatite samples (blue) in Phantom RF1 and RF2 are shown in Figure 4.5. The optimal 
threshold to differentiate between the calcific and hemorrhagic lesion models were determined 
to be -69.9 mrad, 174.0 mrad, and 228.0 ppb for SWAN filtered phase, PDF, and QSM images, 
respectively. These thresholds resulted in a sensitivity values of 91.7%, 97.2%, and 97.2% and 
specificity values of 50.0%, 100%, and 100% for the three image types. PDF and QSM had 
identical performance metrics (AUC = 0.972) since there was a single iron measurement that 
was a known outlier (Figure 4.3, Figure 4.5) caused by an error in phase unwrapping. In 
contrast, the SWAN phase data returned an AUC of 0.644 (Figure 4.4).  
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Figure 4.4: ROC analysis for SWAN filtered phase, PDF, and QSM data. The threshold 
indicates the threshold for which the sum of the true positive rate and the false negative 
rate were optimized. AUC is defined as the area under the curve. 
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Figure 4.5: Histograms of the mean in all calcific and hemorrhagic lesion models over 
three acquisitions for SWAN filtered phase (a), PDF (c), and QSM (e) data. Representative 
images of phantom RF1 are included for the three image types: b) SWAN Phase, d) PDF 
and f) QSM. The colored polygons indicate the material within the samples: 
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hydroxyapatite (blue), iron dextran (red), iron(III) chloride (green), and hemoglobin (gold). 
Units for the SWAN and PDF images are milli-radians; QSM is in units of ppb. One iron(III) 
chloride sample (green arrows) had errors in the phase unwrapping (d), which were 
improved in the QSM (f). 
4.4  Discussion 
We found than the QSM had the best correlation with material concentration out of the three 
image types tested. There have been several studies demonstrating that the susceptibility of 
iron relative to water is between 0.55 and 1.30 ppb per ppm (by mass) of iron in wet tissue 
(176, 209, 224) or approximately 0.14 ppb per ppm iron in dry tissue (230). Since 1 mg Fe/mL 
is equal to 1000 ppm, the slopes calculated in the calibration curves in this study represented 
1.10, 0.87, and 2.57 ppb of susceptibility per ppm of iron for hemoglobin, iron dextran, and 
iron(III) chloride, respectively. This is largely in agreement with the literature studies in humans. 
 
As shown in Figure 4.5b, the SWAN filtered phase images do not provide sufficient phase 
unwrapping as far as 4 cm away from the edge of the phantom. There was not a large enough 
uniform region to determine if the phase would change monotonically with concentration were 
they more centrally located. While ideally a larger phantom would be used to counteract this 
problem with the phase non-uniformities, the size of the head coil limits the overall size of the 
phantom. Patient images that fail to have complete phase unwrapping may limit the capacity of 
radiologists to differentiate between diamagnetic and paramagnetic materials, as it has within 
this phantom. The default SWAN filtered phase images themselves have not been reported on 
extensively in the literature. However, similar sequences from other vendors have 
demonstrated significant phase aliasing in lesions when the phase is processed with a high 
pass filter (144, 231). 
 
In comparison to the SWAN filtered phase images, both the PDF and QSM signal correlated 
much better with material concentration for all material types. The signal within PDF images is 
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proportional to the local magnetic field changes (relative to the main magnetic field) caused by 
the presence of the phantom; in comparison, the QSM signal is equal to the inherent magnetic 
susceptibility of the materials in a given voxel. Because the presence of a material with a large 
susceptibility causes changes in the local magnetic field, they are closely related. However, 
due to the dipole moment of a susceptibility source, there are phase differences in the 
surrounding material that are caused by the susceptibility source some distance away. The 
non-local phase effects can lead to artifacts around the vials in the PDF images (Figure 4.5d) 
that are removed during QSM processing (Figure 4.5f). Therefore, the overall image quality of 
the QSM may be higher than that of the PDF. 
 
Problems with phase unwrapping also impacted portions of the PDF and QSM processing 
pipeline in specific circumstances. In one iron(III) chloride sample with relatively high 
susceptibility, the PDF presented with a phase shift of 2π in one of the three acquisitions. This 
translated to a measured susceptibility in the lesion model where the magnitude of the 
susceptibility was correct, but the sign was negative. The issue was traced back to an error in 
the phase unwrapping of the initial field map, which affected both the PDF and QSM. Since 
lesions with lower and higher concentrations of the material were successfully unwrapped, we 
assume that this is a problem only at specific susceptibility levels that cause aliasing in the field 
map frequency. In the literature, it has been documented that acute hemorrhage featuring 
primarily deoxyhemoglobin has a maximum susceptibility of approximately 1.60 ppb (232); in 
comparison, this lesion had an estimated susceptibility of 2.50 ppb. In phantoms, we will be 
able to develop an algorithm to correct this issue. However, since the composition of lesions 
within the body is not known a priori, it will be difficult to implement in patient exams without 
additional testing. Adjusting the pulse sequence parameters may be a better long term solution 
to avoid phase aliasing within the expected frequency range. 
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We found very good agreement in the QSM across acquisitions. In phantom RF1, the largest 
standard deviation across acquisitions—in all but those samples with uncorrected phase 
wraps—was 31.3 ppb. One study performed QSM in two normal volunteers that were scanned 
at 10 different sites, and in the tissues evaluated, the intra-subject coefficient of variation was 
under 10% (233). Since that study only evaluated healthy patients, they measured a maximum 
susceptibility of approximately 0.14 ppm; in comparison, the highest susceptibility in this study 
(without phase aliasing) was 2.54 ppm to represent an acute or chronic hemorrhage (233). The 
variance in our study increased with higher iron levels, so in patients with lesions, the 
coefficient of variation may increase. 
 
In phantom RF2, we investigated whether we could predict the susceptibility of a lesion by 
summing the calibration curve-derived susceptibility of multiple materials. This simple phantom 
experiment demonstrated that even in a controlled environment, the susceptibility of multiple 
materials is not an additive quantity. Since the susceptibility is proportional to the number of 
free electrons in a material, mixing materials increases the chance of interactions that will bind 
free electrons, hence modifying the susceptibility properties. An example of the phenomenon is 
that while we would expect that mixing diamagnetic hydroxyapatite with paramagnetic iron 
dextran would lower the overall susceptibility slightly, depending on the concentrations mixed; 
there can be a difference of over 50% (Table 4.3). Meanwhile, mixing iron dextran and iron(III) 
chloride did not result in large deviations from the predicted susceptibility. Since we cannot 
estimate the susceptibility in a controlled phantom environment, we must take caution when 
comparing phantom data to human data. The iron concentrations that provide a specific 
susceptibility in phantoms may not translate precisely to human data due to the difference in 
tissue background. 
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There are several limitations to this phantom study. First, the ratio of Fe2+ to Fe3+ in the human 
hemoglobin samples could not be controlled since it was in contact with room air in its 
packaging. Hemosiderin, the primary component of chronic hemorrhage was also not available 
for testing. As previously discussed, the phantoms also are not a perfect substitute for human 
tissue. We did not perform T1- or T2-mapping to determine how biosimilar the background 
material was to brain tissue because we were primarily focused on modeling the T2* effects 
found in hemorrhagic lesions.  
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Chapter 5 
5 Lesion Differentiation in Human Subjects with DECT and PS-MRI 
 
5.1 Introduction 
The correct characterization of intracranial low-density calcification and hemorrhage is a 
challenging clinical problem that may have a direct impact on both diagnosis and clinical 
management. We have identified two promising methods for distinguishing between these two 
lesion categories: dual-energy CT (DECT) and quantitative susceptibility mapping (QSM). 
DECT provides material differentiation through interrogation of the lesion by more than one x-
ray spectra, in effect allowing the photoelectric effect and Compton scattering components of 
attenuation to be determined. In comparison, the goal of QSM is to map the magnetic 
susceptibility of tissue, for which diamagnetic calcium should return a negative susceptibility 
while paramagnetic blood products lead to a positive susceptibility measurement. There have 
been multiple studies in the literature regarding the differentiation of calcific and hemorrhagic 
lesions in the brain (45, 137, 205, 206). However, there have been no studies to date 
comparing these two complimentary modalities, nor have there been prospective clinical trials 
of these new technologies. Both modalities have the potential to provide uniquely valuable 
clinical information about these lesion types through two independent physical mechanisms: 
magnetic susceptibility and x-ray attenuation properties. This chapter details a prospective 
imaging trial in patients with brain lesions with the goal of identifying and characterizing 
intracranial calcifications and hemorrhage in vivo. 
5.2 Methods 
5.2.1 Study Population 
Up to 100 evaluable adult patients with lesions at least 1.0 cm in diameter indicated by foci of 
susceptibility on conventional MR or lesions on routine CT were to be recruited into this trial, 
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which was approved by the local Institutional Review Board. Subjects in the subset of the data 
presented here entered the trial between October 2016 and February 2018. 
Table 5.1: Study inclusion and exclusion criteria. Additional contraindications to MRI can 
be found in Appendix 1 
Inclusion Criteria Exclusion Criteria 
> 18 years of age Failure to obtain consent 
Foci of susceptibility ≥ 1 cm in size on T2*-
weighted GRE of the brain  
OR 
Contraindications to MRI 
 Incompatible implanted device 
 Claustrophobia 
SECT lesion ≥ 1 cm in size and < 100 HU Positive urine pregnancy test 
 
 
5.2.2 Study Design 
Study subjects were recruited from the set of MD Anderson patients undergoing T2*-weighted 
GRE imaging as part of routine clinical MRI of the brain. These studies were imported into 
screening software developed in house (see Appendix 2) on a daily basis. The software 
enabled the user to cycle through all patient datasets sequentially; trained study personnel 
marked images with a likely focus of susceptibility greater than 1 cm in at least one dimension 
for a neuroradiologist to review at a later time. Patients also could be referred to the study by a 
radiologist or their physician if they had a lesion of unknown composition greater than 1 cm in 
any dimension and a measured attenuation of under 100 HU on clinical SECT.  This size 
threshold was chosen to qualify a patient for the trial because DECT analysis becomes less 
accurate as lesion size decreases below 1.0 cm, based on a preliminary study performed by 
our group (136). That study showed that for lesions with attenuations below 100 HU, 
differentiation of calcific and hemorrhagic lesions was not possible when the lesion size 
reached 0.5 cm in diameter; however, due to the limitations of the phantom design, we were 
unable to define a precise size threshold under which DECT did not provide additional 
information over SECT. Because lesions presenting with susceptibility on clinical T2*-weighted 
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GRE often appear larger than they would on pulse sequences that are less vulnerable to 
susceptibility artifacts, such as fast spin echo sequences, using 1 cm as a threshold on GRE 
images allowed for the inclusion of some slightly smaller lesions as measured by CT to qualify 
patients for the study. Furthermore, while a patient was required to have at least one lesion 
over 1.0 cm in diameter on T2*-weighted GRE, many patients had additional lesions present 
that were smaller that were also available for analysis.  
 
From this subset of patients initially screened into the trial, the study radiologist (Dr. Dawid 
Schellingerhout) selected subjects with lesions of unknown composition for potential 
recruitment by a research nurse. The research nurses excluded patients if they declined to 
participate, were deceased or had entered hospice care, had an implanted device incompatible 
with 3.0 T MRI, had the lesion of interest resected, were no longer receiving care at our 
institution, or if they required an interpreter (due to lack of access at our small research center).  
All others were recruited to the study, with informed consent documented. 
 
After screening and study enrollment by research staff, all patients (n = 52, 29 male and 23 
female, aged 25 – 78 years [mean age ± standard deviation: 59.1 ± 12.8 years]) underwent 
non-contrast SECT, non-contrast DECT, and non-contrast MRI at the MD Anderson Center for 
Advanced Biomedical Imaging. Since many of the patients were recruited following screening 
MR, we expected that some lesions would have a SECT attenuation value greater than 100 
HU. Therefore, following image registration of the PS-MRI and CT examinations, the analysis 
was separated into two arms (Figure 5.1): 
1) Lesions with SECT attenuation ≥ 100 HU, for which SECT can be considered a gold 
standard for the diagnosis of calcification, and  
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2) Lesions with SECT attenuation < 100 HU, where no existing gold standard is 
available, and for which analysis would be informed by the phantom analysis and 
concordance/discordance of the QSM and DECT analysis.  
 
Figure 5.1: Study flowchart showing flow from screening to study enrollment and imaging, 
to the analysis of individual lesions in subsets of known calcifications and unclassified 
lesions. 
5.2.3 SECT and DECT Imaging 
SECT and DECT were acquired on a fast kVp-switching capable system (Discovery HD750 
CT; General Electric Healthcare, Waukesha, WI). The SECT scan was identical to the clinical 
routine brain CT performed at our institution; the DECT protocol was informed by the work of 
Nute et al. (136), which indicated that accuracy improved with higher rotation times and 
CTDIvol. These protocols are displayed in Table 5.2. Multiple image sets were reconstructed 
from the DECT exam. Material images with a calcium/water basis pair were generated (136).  
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Table 5.2: Study SECT and DECT imaging protocols. The scan range, image thickness, 
beam width, and field-of-view (FOV) were held constant between the two examinations. 
Technique Parameter SECT DECT 
Scan Type Helical Helical GSI 
Area Maxillary Teeth to Vertex Maxillary Teeth to Vertex 
kVp 120 80/140 
mA 220 600 
Rotation Time (s) 0.8s 0.9 
Pitch 0.531 0.531 
CTDIvol (mGy) 65.2 132.6 
Image Thickness (mm) 0.625 0.625 
Interval (mm) 0.625 0.625 
Beam Width (mm) 20 20 
Scan FOV Head Head 
Display FOV (mm) 250 250 
 
5.2.4 MR Imaging 
Imaging was performed on a 3.0-T MRI system (MR 750, General Electric Healthcare) with an 
8-channel head coil. A three-dimensional (3D) T1-weighted ultrafast gradient echo with 
magnetization preparation (IR-FSPGR) was acquired for anatomical reference. A T2*-weighted 
GRE was acquired for comparison of the signal level for comparison to the clinical MR. A 3D 
susceptibility-weighted angiography (SWAN) sequence was acquired to examine the 
background phase—which is automatically reconstructed—in each material, and a 3D multi-
echo fast gradient recalled echo (MFGRE) was acquired to assess signal changes with 
increasing echo time (TE) and calculate QSM images. Scan parameters are located in Table 
5.3  
5.2.5 Phase-Sensitive MRI Post-Processing 
The first echo of the MFGRE (TE approximately 4.5 ms) was loaded into 3D Slicer to create a 
mask of the brain for Quantitative Susceptibility Mapping (QSM). The cerebrum, brain stem, 
and cerebellum were manually masked, and the resulting logical image set was loaded into 
 97 
 
Matlab (R2016a; MathWorks, Natick, MA) for QSM processing along with the real and 
imaginary DICOM images from the MFGRE. QSM processing was performed using 
Morphology-Enabled Dipole Inversion, which included phase unwrapping and background 
phase removal using Projection onto Dipole Fields as preparatory steps (167, 234, 235). QSM 
reconstruction took approximately one hour per iteration, with an average of six iterations on a 
2.8 GHz Dual-Core Opteron Processor 8220 (Advanced Micro Devices, Santa Clara, CA) with 
up to 128 GB of RAM available.  
Table 5.3: MRI acquisition details for the patient trial, including repetition time (TR), 
inversion time (TI), receive bandwidth (BW), field-of-view (FOV), acquisition matrix 
Sequence IR-FSPGR  T2*-weighted GRE 3D SWAN 3D MFGRE 
# of Echo Times 1 1 6 12 
TE (ms) [min, max] 2.1 15 23.3a [4.7, 61.4] 
TR (ms) 5.7 600 37.6 65.2 
TI (ms) 400 - - - 
Flip Angle 20° 20° 15° 20° 
BW (kHz) 128 128 128 128 
FOV (mm) 220 220 220 220 
Phase FOV (% of FOV) 80 75 80 80 
Matrix 256 x 256 256 x 256 320 x 224 416 x 320 
Slice Thickness (mm) 1.4 5 1.4 1.4 
Scan Time 4:27 2:00 2:49 6:46 
a SWAN provides images that are a weighted average of the six echoes. The average TE is 
listed here. 
 
5.2.6 Image Registration and Segmentation 
Image registration and segmentation were performed in 3D Slicer (Version 4.6, Brigham and 
Women’s Hospital, Boston, MA). All images were co-registered to the axial 3D T1-weighted 
MRI (due to its geometric accuracy) with an affine transformation (236). Foci of susceptibility 
were segmented on the first echo of the registered MFGRE (TE = 4.5 ms) to minimize blooming 
of the lesion. Known calcifications were identified on the registered SECT as those lesions with 
a mean attenuation greater than 100 HU, including physiologic calcifications in the pineal 
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gland, choroid plexus, and falx. Suspected calcifications less than 100 HU were also identified 
on the CT. A circular ROI was placed in the lateral ventricle as a control on the QSM images. 
 
The ROI locations defined in 3D Slicer were saved and loaded into Matlab. Automated 
processing in Matlab was utilized to apply the ROIs to each registered image set for a given 
patient. For each ROI location and image type, the software saved the voxel data, calculated 
the ROI mean and standard deviation, and median.  
5.2.7 Reference Standard 
The current clinical standard for classification of brain lesions as either hemorrhagic or calcific 
is to assign all lesions with SECT attenuation greater than 100 HU as calcification. 
Subsequently, both clinical and imaging features are used to make a probabilistic determination 
of hemorrhage or calcification for lesions under the 100 HU threshold. The following examples 
represent a brief, non-comprehensive demonstration of the clinical thinking that was used to 
define this clinical reference standard:  
 Lesions that exhibited susceptibility on T2*-weighted GRE but were located in the pineal 
gland, choroid plexus, or dura mater were assigned as calcification if there were no 
other signs of bleeding on CT or MRI (237).  
 For lesions in the brain parenchyma, the lesion was labeled as hemorrhage if it was iso- 
or hypo-intense on CT and exhibited significant blooming on T2*-weighted GRE 
compared to the 3D T1-weighted IR-FSPGR sequence or met the other criteria defined 
in Table 2.2.  
 For lesions suspected of hemorrhage with hyperintensity on CT, the clinical history was 
examined to see if hemorrhage was clinically likely. For example, a history of known 
hemorrhagic metastases or recent treatment of a lesion with stereotactic radiotherapy 
were presumed to be hemorrhagic. 
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This clinical reference standard was applied to all lesions by our study neuroradiologist (DS, 18 
years experience), making use of imaging data available from the study and prior routine brain 
studies, as well as clinical information available from the electronic medical record (such as a 
history of recent surgery or radiation). Clinical MR brain imaging at our institution included, but 
was not limited to, T1-weighted, T2-weighted, and T2 FLAIR pulse sequences. CT imaging 
prior to the study exam was not available for all patients.  
 
5.2.8 SECT Analysis 
Lesion data were collected on the SECT. Histogram analysis was performed to assess the 
current clinical ability of CT to differentiate between calcific and hemorrhagic lesions. Receiver 
Operating Characteristic (ROC) analysis was performed utilizing the clinically accepted 
threshold of 100 HU to differentiate between hemorrhage and calcification. 
5.2.9 DECT Analysis 
Lesion data were collected for a calcium/water two material decomposition. ROC analysis was 
performed on the water(calcium) and calcium(water) data individually compared to the 
reference standard. Logistic regression with 5-fold cross validation was performed in Matlab on 
the water(calcium) and calcium(water) with the initial clinical reference standard used as the 
classification metric to determine the probability that specific calcium and water measurements 
were indicative of either hemorrhage or calcification. The logistic fit equation is given by the 
equation below, 
 ln (
𝑝(𝑥𝑤 , 𝑥𝑐)
1 − 𝑝(𝑥𝑤 , 𝑥𝑐)
) = 𝛽0 + 𝛽𝑤𝑥𝑤 + 𝛽𝑐𝑥𝑐 Equation 5.1 
where 𝑥𝑤 represents the water(calcium) means and 𝑥𝑐 represents the calcium(water) means. 
𝛽0, 𝛽𝑤, and 𝛽𝑐 are the fitted coefficients for the logit model resulting from the logistic regression 
(238). Receiver operating characteristic (ROC) analysis was performed to determine the 
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sensitivity, specificity, and area under the ROC curve (AUC) for the DECT diagnostic task. The 
optimal cutoff for the ROC analysis was determined using the Youden index (J) (239): 
 𝐽 = max(𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 + 𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 − 1) Equation 5.2 
Diagnostic accuracy was calculated relative to the reference standard. 
5.2.10 QSM Analysis 
Measurements were made in the cerebrospinal fluid (CSF) of each patient, and the mean 
susceptibility recorded within each patient because CSF is primarily water, which has a known 
susceptibility (𝜒 = -9.05 ppm) (204). A Shapiro-Wilk test was performed on the CSF 
measurements to determine if the distribution of the measured susceptibility was gaussian. The 
QSM of a lesion was considered to be positive for hemorrhage if the measured susceptibility 
was greater than the group sample mean of the CSF measurements across patients, the lesion 
was considered hemorrhagic. If the lesion’s susceptibility was lower than that of the group CSF 
sample mean, the lesion was considered to be calcific. ROC analysis was also performed to 
assess the performance of QSM for the differentiation of calcific and hemorrhagic lesions with 
an optimal cutoff at the Youden index (Equation 5.2). Diagnostic accuracy for each modality will 
be considered relative to the reference standard.  
5.2.11 Statistical Analysis 
McNemar’s test was used to compare the binary DECT and QSM classifications—calcification 
or hemorrhage—for all lesions overall and within each subgroup (SECT < 100 HU and SECT ≥ 
100 HU) to test for consistency in classification between the two modalities (240). The level of 
the concordance was assessed using Cohen’s Kappa statistic (241).  
 
The marginal utility of both DECT and QSM will be determined by comparing the ROC analysis 
of the individual modalities to the ROC characteristics of SECT alone (242, 243). The optimal 
thresholds for each modality were chosen from ROC analysis of the whole dataset. 
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5.3 Results 
5.3.1 Study Population 
Screening data is shown in Figure 5.2, including the total number of unique patients viewed by 
study personnel, the number of patients having a preliminary lesion marked, and the number of 
patients approved by the study’s neuroradiologist for recruitment. Of the 754 patients deemed 
eligible for the study based on clinical T2*-weighted GRE imaging, a total of 702 were either 
excluded, declined to participate, or were unable to be contacted. A total of 52 patients were 
scanned from October 2016 to February 2018. Two patients were excluded from this analysis 
due to image artifacts due to motion in the MFGRE pulse sequence used to generate the QSM 
images. Within this population, there were a total of 328 total foci of susceptibility identified; the 
initial clinical classification used as a reference standard indicated 189 calcifications and 139 
hemorrhagic lesions in total. 
 
Figure 5.2: Subject accrual flow chart 
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5.3.2 SECT Analysis 
There were a total of 179 lesions with a SECT attenuation greater than or equal to 100 HU. A 
histogram with kernel density estimates demonstrates the distribution of SECT HU for the 
hemorrhage and calcification groups as defined by the reference standard (Figure 5.3).  
 
Figure 5.3: SECT values for lesions classified as hemorrhage and calcification by the 
reference standard. The dotted black line marks the current established threshold for 
differentiating between calcification and hemorrhage on SECT (100 HU). Note that 
applying this threshold rigidly would misclassify multiple calcific lesions as hemorrhagic, 
based on initial clinical classification. 
 
While the kernel density estimates in Figure 5.3 overlap, the hemorrhage with the highest 
attenuation measured 53.7 HU; the calcification with the lowest attenuation measured 67.5 HU. 
As a result, any threshold between 53.7 and 67.5 HU would effectively separate the 
hemorrhage and calcification present in this dataset. The ROC analysis returned an optimal 
threshold of 67.5 HU, at which the accuracy, sensitivity, and specificity were all 100%. 
However, using a threshold of 100 HU, which is currently utilized clinically, has an accuracy of 
95.1%, sensitivity of 100%, and specificity of 91.8% 
  
 
 
 103 
 
5.3.3 DECT Analysis 
ROC analyses of the calcium(water) and water(calcium) data returned optimal 
thresholds of 11.76 mg Ca/mL and 1030.7 mg H2O/mL, respectively. The calcium(water) 
images provided better discrimination between the hemorrhagic and calcific lesions than the 
water(calcium) images (Figure 5.4). Combining the data from both DECT image types, the 
logistic regression of the calcium(water) and water(calcium) data returned the linear 
combination coefficients found in Table 5.4. The calcium(water) was the only statistically 
significant parameter in the fit. The calcium density is the primary predictor, which can be seen 
visually in Figure 5.6a, in which a line that represents the optimal threshold between the calcific 
or hemorrhagic lesions has been superimposed on a scatter plot. The threshold that optimized 
the Youden index (Equation 5.2) for the logit model was a linear metric (𝛽0 + 𝛽𝑤𝑥𝑤 + 𝛽𝑐𝑥𝑐) of -
2.68 (Figure 5.6b). The mean and standard deviation for each lesion type as defined in the 
model are in Table 5.5 for SECT, water(calcium), and calcium(water) image types, and the 2 x 
2 classification matrices are in Figure 5.5. The overall accuracy of this model was 99.7% 
(327/328) amongst the entire dataset (Figure 5.5, Table 5.10), 100% (179/179) amongst SECT-
proven calcifications, and 99.3% (148/149) amongst lesions with SECT < 100 HU. The 
sensitivity and specificity in the full dataset were 99.3% (134/135) and 100.0% (193/193). 
Table 5.4: DECT logistic regression. The equation for the fit is given in Equation 5.1. A p-
value of less than 0.05 represents the statistical significance of the parameter within the 
model (indicated by *). 
 Coefficient t Statistic p-value 
Intercept (𝛽0) -122.900 -1.77 0.077 
Water(Calcium) (𝛽𝑤) 0.112 1.66 0.096 
Calcium(Water) (𝛽𝑐) 0.549 4.23 < 0.001* 
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Figure 5.4: ROC curves for Water(Calcium) and Calcium(Water) data compared to the ROC 
curve for SECT with a threshold of 100 HU. 
 
Table 5.5: Mean SECT, water(calcium), and calcium(water) measurements for lesions 
classified as hemorrhage and calcification in the DECT-based logistic regression. 
DECT Classification Hemorrhage (n = 133) Calcification (n = 195) 
 Mean Standard  
Deviation 
Mean Standard  
Deviation 
SECT (HU) 34.9 8.3 177.6 86.1 
Water(Calcium) (mg/mL) 1021.9 7.0 1048.7 16.7 
Calcium(Water) (mg/mL)  5.2 2.1 44.7 24.4 
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Figure 5.5: a) Classification matrices for the DECT-based logistic model compared to the 
reference standard and b) the ROC curve for the DECT and SECT classification schemes. 
 
Figure 5.6: DECT water(calcium) and calcium(water) data classified by the reference 
standard. a) A scatter plot of the water(calcium) and calcium(water) means for all 328 
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lesions. The dotted black line represents the optimal threshold between calcification and 
hemorrhage in the logistic model, where a linear combination of the water and calcium 
data is equal to -2.675. b) The logistic regression compared to the reference standard. 
 
5.3.4 QSM Analysis 
Across the 50 patients studied, the mean susceptibility of CSF was 27.5 ± 10.1 ppb (Figure 
5.7), and normality was confirmed with a Shapiro-Wilk test (p = 0.71). Of the 328 susceptibility 
lesions identified, by QSM, 192 lesions were classified as calcifications (-109 ± 129 ppb) and 
136 as hemorrhage (730 +/- 457 ppb) using the mean QSM of CSF as a threshold, for a total 
accuracy of 98.5% (323/328). However, a threshold set at 37.6 ppb (CSF mean plus one 
standard deviation) satisfies the Youden index (Figure 5.8). The means and standard 
deviations of the SECT and QSM for each classification are in Table 5.6, and scatterplots are 
showing the relationship between SECT and susceptibility are shown in Figure 5.9. Compared 
to the reference standard, the diagnostic accuracy using the 37.6 ppb threshold was 99.4% 
(326/328) in the whole dataset, 100% (149/149) in lesions with SECT < 100 HU, and 98.9% 
(177/179) in lesions with SECT ≥ 100 HU. The sensitivity and specificity were 98.5% (133/135) 
and 100% (193/193) in the whole dataset, 100% (133/135) and 100% (14/14) for lesions under 
100 HU, and specificity was 100% (179/179) in lesions greater than 100 HU. In this final 
category, sensitivity could not be calculated because there were no cases positive for 
hemorrhage. 
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Figure 5.7: Histogram of the CSF susceptbility measurements for 50 patients with a 
Gaussian fit (left). A quantile-quantile plot is shown on the right to display the deviation 
of individual measurements from the displayed normal distribution (right). A Shapiro-Wilk 
test did not reject the null hypothesis that the distribution was Gaussian (p = 0.71). 
Table 5.6: Mean SECT and QSM measurements for lesions classified as hemorrhage and 
calcification based on a threshold of 37.6 ppb. 
 Hemorrhage (n = 135) Calcification (n = 193) 
 Mean Standard  
Deviation 
Mean Standard  
Deviation 
SECT (HU) 36.8 18.5 177.7 86.4 
QSM (ppb) 741.8 445.8 -117.6 97.9 
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Figure 5.8: a) Classification matrices for the QSM-based logistic model compared to the 
reference standard and b) the ROC curve for the QSM and SECT classification schemes. 
 109 
 
 
Figure 5.9: a) Mean QSM for each lesion versus the SECT attenuation in HU. Note that two 
lesions measure both over 100 HU and well above a susceptibility of 37.6 ppb. These two 
lesions are known as outliers where calcification is present adjacent to a vein or 
hemorrhagic lesion. b) Histograms of the QSM mean for calcifications and hemorrhages 
with kernel density estimates of the distributions. The optimal threshold of 37.6 ppb is 
shown in yellow in both plots. 
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Figure 5.10: A 48-year old female patient with a history of right frontal craniotomy and a 
lobular mass consistent with cavernoma presenting as a large focus of susceptibility on 
the MFGRE (TE = 14.5 ms) (a). The SECT (b) demonstrates a densely calcified region 
within the lesion (red outline) with HU greater than 100. (c) QSM of the lesion shows high 
magnetic susceptibility thoughout the lesion with regions of apparent aliased signal. 
The calcification does not present with the expected negative susceptibility. 
 
 
Figure 5.11: A 73-year old female patient with a history of metastatic melanoma with 
Gamma Knife therapy. (a) The globus pallidus shows mineralization consistent with 
aging that causes low signal on the MFGRE (TE = 14.5 ms). (b) SECT shows a small 
calcification (green outline) within the globus pallidus with attenuation over 100 HU. (c) 
QSM shows consistently high signal in the globus pallidus despite the presence of 
calcification, but other calcific lesions (yellow arrows) demonstrate the expected 
negative susceptibility. 
5.3.5 Statistical Analysis 
The 2 x 2 classification matrices comparing the DECT and QSM classifications for the 
whole dataset, lesions with SECT < 100 HU, and lesions with SECT ≥ 100 HU are found in 
Table 5.7 - Table 5.9. For each of these classifications respectively, McNemar’s test returned p 
= 1.000, p = 1.000, and p = 0.500, indicating that QSM and DECT were concordant. 𝜅 was 
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equal to 0.981 and 0.964 for the whole dataset and those lesions under 100 HU; 𝜅 could not be 
computed for lesions over 100 HU because DECT did not indicate the presence of any 
hemorrhagic lesions. Therefore, concordance between the two modalities was very high, and 
we can assume that the lesions under 100 HU for which QSM and DECT are in agreement 
(133 hemorrhagic lesions, 15 calcific lesions) are accurately classified. Accuracy, sensitivity, 
specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the 
ROC curve (AUC) are tabulated in Table 5.10.  
 
Table 5.7: Classification matrix for the QSM classifications of all lesions versus the 
DECT classifications for all lesions 
Whole Dataset 
QSM 
Hemorrhage Calcification 
D
E
C
T
 
Hemorrhage 133 1 
Calcification 2 192 
Table 5.8: Classification matrix for the QSM classifications of all lesions versus the 
DECT classifications for lesions with SECT greater than 100 HU. 
SECT > 100 HU 
QSM 
Hemorrhage Calcification 
D
E
C
T
 
Hemorrhage 0 0 
Calcification 2 177 
Table 5.9: Classification matrix for the QSM classifications of all lesions versus the 
DECT classifications for lesions with SECT less than 100 HU. 
SECT < 100 HU 
QSM 
Hemorrhage Calcification 
D
E
C
T
 
Hemorrhage 133 1 
Calcification 0 15 
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Table 5.10: Comparison of the ROC analysis for SECT (threshold = 100 HU), DECT, and 
QSM ROC analyses. Values were calculated for water(calcium) and calcium(water) images 
in the whole dataset. Dashes represent values that could not be calculated due to division 
by zero. The AUC for the SECT data was calculated assuming a threshold of 100 HU.  
Data 
Subset 
Classification Method Accuracy Sensitivity Specificity PPV NPV AUC 
Whole 
Dataset 
SECT (HU) 95.1 100 91.8 89.3 100 0.976 
Water(Calcium) 90.9 92.5 89.7 92.5 89.7 0.970 
Calcium(Water) 99.3 98.5 99.0 98.5 100 0.997 
DECT (Logistic Model) 99.7 99.3 100 100 99.5 0.998 
QSM (ppb)  99.4 100 98.5 100 99.0 0.991 
SECT < 
100 HU 
SECT (HU) 89.3 100 0 89.3 -  
DECT (Logistic Model) 99.3 99.3 100 100 93.8  
QSM (ppb)  100 100 100 100 100  
SECT ≥ 
100 HU 
SECT (HU) 100 - 100 - 100  
DECT (Logistic Model) 100 - 100 - 100  
QSM (ppb)  98.9 - 98.9 0 100  
 
5.4 Discussion 
This study evaluated both DECT and QSM for the identification of calcification and hemorrhage 
in vivo. Our initial clinical reference standard was based on a radiologist’s interpretation of the 
lesion based on the available prior clinical MRI imaging (including T2*-weighted GRE and T1- 
and T2-weighted imaging) and the study exams. This standard was found to be highly 
concordant with the subsequent quantitative analyses. It is of paramount importance to the 
interpretation of the results presented here that the study was performed in an outpatient 
population with chronic lesions. Patients presenting with acute symptomatic lesions in an 
emergent setting frequently have hemorrhagic lesions of higher attenuation, and we would 
anticipate that we would see additional overlap in the SECT attenuation of the calcific and 
hemorrhagic lesions if these patients were included in the trial. As the overlap in attenuation 
would increase, we would expect that the results, particularly for the DECT analysis, would 
result in worse differentiation. 
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We confirmed the efficacy of QSM for the accurate differentiation of diamagnetic and 
paramagnetic materials (45, 205, 206). DECT calcium(water) and the DECT logistic regression 
both had higher accuracy compared to SECT with a 100 HU threshold for this lesion 
classification. As DECT becomes increasingly available clinically, it may provide additional 
avenues for the diagnosis of hemorrhage, particularly for patients in emergent settings or those 
with contraindications to MRI.  
 
There are inherent difficulties in determining the reference standard for these lesions because 
there is no true gold standard under 100 HU on SECT. In cases where no true gold standard 
exists, it has been established within the statistical literature that agreement statistics between 
two diagnostic tests provides valuable diagnostic information (244, 245). Because we were 
differentiating between two diagnostic classes, calcification and hemorrhage, we utilized the 
methodology developed by McNemar (240). In a two by two contingency table, such as Table 
5.7, the concordant results in which both tests agree are ignored in McNemar’s test, and 
instead the null hypothesis is that the probability of discordant measurements that are positive 
by test 1 and negative on test 2 is equal to those that are positive on test 2 and negative on test 
1 (240). Therefore, if the null hypothesis is rejected, the two tests provide different results. In 
this case, McNemar’s test did not reach statistical significance when testing QSM against 
DECT for the differentiation of chronic hemorrhage and calcification, so we could assume that a 
lesion that had the same classification by both imaging modalities being tested was an 
accurate diagnosis. 
 
With access to follow-up imaging for nearly all patients, we were able to establish a clinical 
reference standard using both CT and MRI. However, this was still based on a conventional 
understanding of the properties of calcification and hemorrhage on conventional imaging; we 
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have shown in this work that intracranial calcification can have SECT attenuation values under 
100 HU (Figure 5.3). We also considered the results of the DECT and QSM to be accurate if 
the two modalities were concordant. Prior studies had only diagnosed calcification if the lesion 
was greater than 100 HU or they had pathologic proof (45, 205, 206). Chen et al. found 
Morphology-Enabled Dipole Inversion (MEDI) QSM, which was also utilized in this study, to 
have a sensitivity of 89.5% and specificity of 94.5% for detection of hemorrhage and 
calcification (45). Our study focused on a slightly different task, in which segmentation was 
performed on the MFGRE and SECT images. However, by utilizing foci of susceptibility that 
represented known physiologic calcifications, we were able to demonstrate very high sensitivity 
and specificity for QSM at 99.4% and 98.5%, respectively, within the whole dataset. 
 
The work of Nute et al. was the first to utilize DECT imaging to differentiate between 
intracranial calcification and hemorrhage by utilizing several phantom studies (135, 136). We 
utilized the protocol recommended in said work and a calcium/water material decomposition 
(136). Despite this study being developed as a corollary of that phantom work, there were 
several key differences as we translated this work from phantoms into humans. First, we did 
not investigate the use of multiple image thickness values. It is likely that there would be 
significant image quality improvements in the DECT images if a thicker image were used, at the 
expense of losing spatial resolution and being unable to analyze smaller lesions. The second 
was that we found that the 68 keV data, which formed the z-axis in a 3D feature space, was 
highly correlated with the calcium(water) data from the patient lesions and could be eliminated 
from the differentiation algorithm (136). While the SECT attenuation of each lesion was still 
used as a reference point for reporting purposes, this simplifies the analysis in the long term, 
which could encourage clinical use.  
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In comparison to another DECT study differentiating calcific and hemorrhagic lesions, our study 
had a larger proportion of chronic hemorrhagic lesions since the clinical imaging was 
conducted on a purely outpatient basis, an was not performed in an emergency room or 
inpatient setting (137). Additionally, ROC analysis of SECT data showed that an optimal 
threshold could be found without using DECT to differentiate between chronic hemorrhage and 
calcification based on density alone. There was a total of 53 lesions that had a mean SECT HU 
between 40 and 100 HU, and we estimate that 16 of them were calcific based on concordance 
between the DECT and QSM. Of those 53 lesions within an HU range expected of acute or 
sub-acute hemorrhage (3, 26, 246), 31 did not have a SECT attenuation higher than 50 HU. 
The primary disadvantage of this is that chronic hemorrhagic lesions may not be readily visible 
relative to the brain parenchyma on DECT because they have similar attenuation levels as gray 
and white matter. Therefore, DECT may be of limited utility for patients that cannot undergo 
conventional T2*-weighted GRE MRI to identify regions where susceptibility is present. 
However, results of a previous phantom study from our groups demonstrated that fast-kVp 
switching CT was able to differentiate between calcific and hemorrhagic lesions of comparable 
SECT HU above 50 HU (136). The inclusion of acute hemorrhage in future trials will allow us to 
confirm the results of the phantom study. 
 
Two patients had to be excluded from the study due to motion artifacts that corrupted the 
MFGRE data used for QSM processing. The pulse sequence used in this study was comprised 
of 12 echo times, which increased the scan time compared to the SWAN sequence that was 
utilized in our phantom studies (Chapter 4). The MFGRE sequence is also a three-dimensional 
pulse sequence, which is inherently more susceptible to motion artifacts throughout the entire 
scan field of view compared to two-dimensional sequences. For clinical implementation, it 
would be advantageous to limit the acquisition time in order to lower the chance of non-
diagnostic images that could not undergo additional processing. There are many possible 
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avenues to consider in order to achieve this goal. The number echoes could be lowered to six 
or eight, and the spatial resolution could be reduced compared to this research sequence. 
Overall, this indicates that DECT, with acquisition times under 30 seconds, may be a valuable 
alternative for differentiating calcific and hemorrhagic lesions in patients that are unable to 
remain still for long periods of time due to their medical condition during an MR exam. 
 
QSM remains time intensive at approximately one hour per iteration for an average of six 
iterations. This time could be lowered significantly by utilizing servers with higher processer 
speeds than those available for use in this study. Decreasing the spatial resolution of the 
MFGRE pulse sequence, particularly the number of images per slab, would also reduce the 
computation time required for the QSM. Except for two calcifications which were adjacent to 
known hemorrhage or venous structures, QSM proved to be highly sensitive in identifying both 
hemorrhage and calcification. The QSM processing in the MEDI algorithm includes the option 
for using a spherical mean value to help acquire the true susceptibility in brain parenchyma. 
This can minimize the appearance of subtle artifacts that may remain after MEDI processing by 
averaging data in a sphere surrounding a specific voxel but may cause additional volume 
averaging near anatomical edges. While lesion edges were generally avoided when placing 
ROIs in this study, it may have contributed to the errors seen near chronic hemorrhage with 
very high susceptibility (Figure 5.10, Figure 5.11). The lesions that were misclassified were 
both small calcifications surrounded by high positive susceptibility regions. Because the 
magnitude of the magnetic susceptibility in iron-based lesions (including mineralization in deep 
gray matter) is much higher than that of calcification, any averaging present may result in small 
calcific lesions being masked by adjacent iron deposition. Adjusting the spherical mean value 
diameter setting may be of interest to clinicians as this method gains wider acceptance in the 
clinic in order to optimize the post processing for a given application to balance the 
visualization of small calcifications and minimization of artifacts. 
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There were several other limitations in this study. The first is that screening was performed 
nearly entirely on T2*-weighted GRE MRI, which is highly sensitive to chronic hemorrhage. 
Because most patients entered into the study did not have a head CT available for comparison, 
there was no way to guarantee that lesions were a) visible on CT and b) within the desired 40 – 
100 HU range. Because the lesions were not necessarily visualized on SECT or DECT, 
segmentation of the lesions of interest (outside known calcifications) was performed on the 
MFGRE. Some disadvantages of using the MFGRE for this purpose include lower spatial 
resolution than the SECT and the potential for blooming artifact. Blooming, in particular, would 
cause an ROI to be larger than the actual lesion and could degrade the DECT results by 
including normal brain tissue surrounding the lesion within the volume of interest. The second 
limitation is that the study was performed at an ambulatory clinical research center rather than 
in an emergent or inpatient setting. The study location further skewed the study towards cases 
of chronic hemorrhage because the majority of patients with acute hemorrhage were too ill to 
undergo the imaging required for the study. This ultimately meant that ROC analysis was able 
to find a SECT threshold that had slightly higher accuracy than the DECT in this dataset. We 
know from clinical experiences at other institutions that this would not be the case were acute 
hemorrhage more prevalent in the study (137). 
 
Future work will include continued patient accrual through September 2018 or until 100 patients 
have been scanned. We plan on investigating whether DECT monoenergetic images may 
further assist in the differentiation of hemorrhage and calcification. Additionally, we have a 
multi-modality dataset that can also be used to determine the optimal monoenergetic energy for 
comparisons to SECT, investigate the extent of blooming artifact compared to the quantitative 
susceptibility of lesions, and further quantify the magnetic susceptibility of normal tissues within 
the brain. This extensive dataset may enable further comparisons in this dataset to DECT 
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material decompositions utilizing iron as in the material decomposition. In addition, this work 
justifies a future clinical trial which would investigate the differentiation of acute hemorrhage 
and calcifications in an emergent setting. 
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Chapter 6 
6 Conclusions 
 
6.1 Summary of Findings 
In this dissertation, we explored the application of DECT and Phase-Sensitive MRI (PS-MRI) 
techniques for the classification of intracranial calcific and hemorrhagic lesions. On 
conventional T2*-weighted MRI, both these lesion types are indicated by the presence of dark 
spots in the image that result from the presence of a material with a magnetic susceptibility 
different from the surrounding normal tissue. Calcium is diamagnetic while most iron-based 
compounds are paramagnetic, so utilizing the MRI phase in susceptibility-weighted pulse 
sequences is a promising technique for differentiating the two lesion types.  
 
In Chapter 3, we validated phantom materials that modeled the signal properties of calcific and 
hemorrhagic lesions on a multi-echo GRE pulse sequence. T2*, the time it takes for a 
material’s spins to dephase when field inhomogeneities are present, was a quantity that we 
could use to compare our phantom materials to the biological T2* values for calcification and 
hemorrhage in the literature. We investigated a total of seven materials (two calcium-based and 
five iron-based) for use in an MR phantom. Four materials were chosen for use in the final two 
phantoms based on their T2* values: hydroxyapatite, iron dextran, iron(III) chloride, and human 
lyophilized hemoglobin powder. Our lab developed hydroxyapatite agarose gels for use in a 
DECT phantom (135), but few studies were available in the literature which utilized calcium-
based MRI phantoms (208, 215, 247). Because of this work, we determined that powdered 
hydroxyapatite embedded in agarose does adequately model the T2* decay properties of low-
density intracranial calcifications. Similarly, we determined that three iron-based compounds—
iron dextran, iron(III) chloride, and human hemoglobin—had T2* values comparable to that of 
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hemorrhagic lesions and iron-laden deep gray matter, with T2* between approximately 5 and 
35 ms (209-211). 
 
After demonstrating that we could model the appearance of hemorrhage and calcification on 
T2*-weighted GRE magnitude images in phantoms, we began to assess the feasibility of 
differentiating between the two iron- and calcium-based models with PS-MRI (Chapter 4). The 
phantoms developed in Chapter 3 provided a simple physics model for testing different PS-MRI 
methods. The first method tested in phantoms was the automatically-processed filtered phase 
image from the SWAN pulse sequence. We found that these phase images did not have 
sufficient phase unwrapping, and, as a result, the phase did not correlate well with increasing 
concentration of either diamagnetic or paramagnetic materials (Figure 4.3). The second 
method tested was Projection onto Dipole Fields (PDF), which results in a background 
subtracted phase image. These images were of higher quality than the SWAN phase images, 
and we could visually discriminate between calcification and hemorrhage. There was a high 
correlation between the phase and all materials except iron(III) chloride. Additionally, there was 
some shading around samples with high positive susceptibility that would be a confounder for 
clinical diagnosis of calcification and hemorrhage (Figure 4.5d). Finally, the PDF image was 
used as an input for Quantitative Susceptibility Mapping (QSM) in which the background 
subtracted phase (which provides a map of the local magnetic field) was used to solve an 
inverse problem that returns the distribution of magnetic susceptibility within the phantom. The 
QSM processing was able to eliminate some of the errors in the iron(III) chloride samples found 
in the PDF phase images. The improvement in the QSM of the iron(III) chloride over the PDF is 
likely due in part to the additional spherical mean value averaging that helps to arrive at the 
true susceptibility within a reasonably uniform region. Additionally, the shading surrounding 
several lesion models in the PDF images was resolved in the QSM. Overall, QSM had the 
highest correlation between material concentration and susceptibility, and the images are easily 
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interpretable—diamagnetic materials returned negative susceptibility while paramagnetic 
materials had a positive susceptibility. 
 
Given the results of Chapter 4, we focused on the ability of SECT, DECT, and QSM to 
differentiate between calcific and hemorrhagic lesions in vivo (Chapter 5). The human trial 
accrued a total of 52 patients with 328 lesions. Of those lesions, 179 were classified as 
calcification definitively by SECT (HU ≥ 100). Overall, a clinically-derived reference standard 
identified 195 likely calcifications (14 under 100 HU) and 133 hemorrhages. Both SECT and 
DECT were able to identify known calcifications with 100% accuracy. QSM classified two 
definitive calcifications incorrectly; one was located near a vein which masked the calcification, 
and the other was surrounded by likely hemorrhage. Below a SECT threshold of 100 HU, QSM 
was 100% accurate compared to a clinically-derived reference standard. While DECT (and 
SECT with an optimized differentiation threshold) narrowly remained the most accurate 
modality for identifying hemorrhage and calcification in this dataset, it must be qualified by the 
fact that our dataset did not include any hemorrhage with an attenuation between 53 HU and 
100 HU on SECT, and no overlap in HU between the hemorrhagic and calcific lesions was 
present.  
6.2 Advances in Knowledge 
This work provided several advances in knowledge and utilized a unique study design which 
examined two imaging modalities to arrive at a consensus on the diagnosis of hemorrhage and 
calcification. The first advance was the creation of an MR phantom with calcific and 
hemorrhagic lesions available for direct comparison with phase-sensitive MRI post-processing 
algorithms. Overall, there are very few phantoms described in the MR literature that specifically 
included calcium as a material of interest (208, 215, 247). Valdés Hernández et al. did directly 
compare iron and calcium in a phantom using calcium carbonate and superparamagnetic iron 
oxide nanoparticles in alginate beads, which is a gel similar to agarose (215). They utilized the 
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phantom to differentiate between calcification and hemorrhage models using only T1-weighted 
and T2-weighted magnitude image features. However, their lesion models were approximately 
1-3 mm in diameter, which would not have provided an adequate volume for quantitative 
measurements within the lesion models (215). More importantly, they were unable to control 
the exact concentration of their gels. Utilizing phase-based image processing such as QSM 
allows us to interrogate the imaging data for a quantity that directly correlates with the 
concentration of these material types as well as providing thresholds for the accurate 
differentiation of calcification and hemorrhage. 
 
We also validated several materials that could potentially simulate hemorrhage on MRI. There 
are several quantities of interest that we would ideally like to match in order to simulate these 
lesions adequately in phantoms. The first, which we investigated extensively, was the T2* value 
associated with various concentrations of materials. This quantity defines the exponential 
decay of the signal in a multi-echo T2*-weighted GRE sequence as the echo time (TE) 
increases. This has been extensively reported in the literature for many tissue types (209-212). 
The second quantity of interest is the magnetic susceptibility, which should increase gradually 
with increasing iron content to mimic most iron-laden tissues. We validated that our materials, 
particularly iron dextran, behaved very similarly to human hemoglobin (primarily in the form of 
methemoglobin). While most studies utilize superparamagnetic iron oxide nanoparticles 
(SPIOs) in phantoms, they are very expensive relative to iron dextran (which can be acquired 
through most chemical suppliers), and the ratio of susceptibility to iron concentration is 
incredibly high, outside of the biologically-expected range, due to the superparamagnetic 
properties of the nanoparticles (see Section 2.4.3). Therefore, very small differences in SPIO 
concentration could cause a very large shift in the susceptibility, and errors in the physical 
measurement of the compound would have an unduly large impact on the phantom data. 
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The design of our patient study is also unique, and—to our knowledge—we are the first group 
to attempt an investigation of intracranial lesions specifically under 100 HU. While DECT and 
QSM have been used to differentiate between calcification and hemorrhage in vivo in individual 
retrospective studies (137, 205, 206), there have been no studies attempting to compare the 
two modalities directly and prospectively. Because we acquired non-contrast SECT in the same 
session as non-contrast DECT and phase-sensitive MRI, we could compare the conventional 
methods of identifying calcification to that of more recent image processing methodologies. We 
included naturally occurring calcifications in our analysis. This allowed us to analyze calcific 
lesions within nearly every patient, and the degree of calcification in these normal tissues (i.e., 
the pineal gland and choroid plexus) returned highly varied attenuation levels, definitively 
demonstrating the presence of calcification under the 100 HU SECT threshold currently used 
clinically.  
 
Along with other studies in the literature, we have been able to help establish the range of 
susceptibility values expected within chronic hemorrhagic lesions. This is important moving 
forward so that pulse sequences that will be used for QSM processing can be optimized to 
work for a wide variety of patients. While we did not optimize our pulse sequence for 
visualization of the vasculature, we were able to easily visualize and identify hemorrhagic 
metastases as well as calcific lesions under 100 HU on SECT.  
6.3 Limitations 
There are several major limitations to the methodologies employed in this study. The first is that 
the samples in the phantom were cylindrical, and therefore resulted in orientation dependence 
on the susceptibility-weighted MRI sequences. It would be advantageous to develop spherical 
molds of various sizes to eliminate this orientation dependence; it would also allow for the vials 
themselves to be eliminated from the phantom design. While the vials did not cause artifacts 
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within the QSM images, removing them would minimize the number of abrupt boundaries in the 
susceptibility map and may better represent the shape of most lesions within the brain. 
 
One of the main limitations to potential clinical translation discovered during this work is the 
time required for QSM processing of large datasets. A patient dataset took approximately six 
hours to reconstruct. However, this reconstruction was performed on a server with eight 2.8 
GHz Dual-Core Opteron 8220 (Advanced Micro Devices, Santa Clara, CA) processors, which 
were released in 2007. Given modern processing speeds, reconstruction times should be 
approximately 1 hour, provided sufficient RAM is available on the system. While this process 
was performed offline for this study, the MEDI algorithm has been licensed to MR 
manufacturers and may become commercially available in the near future. 
 
Finally, the patient population enrolled in the clinical trial was heavily weighted towards patients 
with chronic hemorrhage, as discussed extensively in Section 5.4. While this represents the 
majority of the outpatients with hemorrhagic lesions at our oncology-focused institution, it is not 
representative of what may be seen in an emergent or inpatient setting, particularly at hospitals 
that are more likely to treat hemorrhagic stroke or traumatic brain injury. Including patients with 
acute hemorrhage in the study would allow us to study the true differentiation of hemorrhage 
and calcification with SECT attenuation levels between 60 and 100 HU in a more 
representative patient population. However, it would be difficult to acquire all of the imaging for 
this study in one imaging session. Given the potential for temporal evolution of acute 
hemorrhage and/or surgical intervention, the temporal matching of the CT and MRI exams 
would be of even greater importance and be much more difficult to achieve without 
compromising care for these patients. 
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6.4 Future Work 
There are multiple avenues for research to be pursued using this dataset—both phantom and 
human—as an extension of this work. The phantom data provides a reference for many 
different iron-based materials that are similar to materials found within the body. By utilizing 
phantoms akin to those created throughout the course of this work, we can further investigate 
image quality concerns that may arise during QSM processing, such as phase aliasing. By 
replicating these image quality issues in phantoms, we can test additional algorithms to detect 
and correct for potential errors. The phantoms may also be used as a reference to begin iron 
quantification studies using QSM and DECT. We can use the phantom data that has already 
been acquired, along with the patient data, to assess the accuracy of QSM when performed 
with fewer echoes or other pulse sequences, such as the ultrashort echo time sequence 
acquired alongside the other susceptibility-weighted sequences (248). 
 
Within the patient dataset, one research area in which our dataset is particularly suited is in 
comparing image quality and quantitative metrics between SECT and DECT in both normal 
tissue and lesions. There are no existing guidelines for translating diagnostic thresholds from 
years of experience with SECT to the new paradigm of DECT. While some vendors provide a 
mixed image which may be a reasonably close match to a conventional 120 kVp SECT, other 
vendors may recommend using monoenergetic images as a replacement for SECT. Therefore, 
it is paramount that we are able to either find monoenergetic energies for which various tissue 
compartments have mean CT numbers equal to the 120 kVp SECT Hounsfield Unit, or that we 
find an algorithm that can convert a SECT threshold to its monoenergetic equivalent.  
 
We acquired several pulse sequences as a part of the clinical trial that were not explicitly 
described in this dissertation. Several may be utilized in other studies for differentiation of 
calcification and hemorrhage. We acquired an Ultrashort Echo Time (UTE) sequence which 
 126 
 
can provide signal even within the bony anatomy, and may assist in the identification of dense 
calcification which has a very low proton density and, consequently, a low signal on 
conventional MRI sequences. We also have acquired a synthetic MR sequence which can be 
processed into T1-weighted, T2-weighted, and Proton Density-weighted image series as well 
as quantitative maps of T1 and T2. We plan on investigating how results from these two 
sequences correlate with the data acquired with QSM.  
 
Ultimately, we would like to see both DECT and QSM adopted for appropriate brain imaging in 
the clinic. We have extensively studied quantitative differentiation of calcific and hemorrhagic 
lesions on a fast kVp switching DECT system, but to adapt this protocol to other systems, it 
would be useful to repeat some of the imaging performed by Nute et al. to optimize the 
workflow (136). Using images from our current study, we could also perform a reader study to 
determine if chronic hemorrhagic lesions can be visualized on DECT without registration to an 
MR image. Following these steps, implementing DECT for routine brain scans either in the 
inpatient or outpatient settings would require that we reduce the CTDIvol (currently 132.6 mGy). 
To counteract the increase in noise caused by lowering the dose, we would also increase the 
image thickness to 3.75 mm in an attempt to maintain reasonable signal-to-noise ratios. Finally, 
we would need to develop the workflow so that all required DECT images (calcium, water, 
SECT equivalent) would be reconstructed automatically and sent to PACS for radiologists’ 
viewing. 
 
Implementing QSM in a clinical environment may be more technologically challenging than 
introducing DECT. First, the MFGRE sequence we used had an acquisition time near 7 
minutes in patients. This would need to be shortened for clinical acceptance, and so we would 
likely need to decrease the number of echoes acquired and potentially adjust the spatial 
resolution. Trained staff would be required to initiate QSM processing, which requires 
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significant computational power to complete in a reasonable amount of time. This may become 
easier as several vendors, including General Electric, have licensed the MEDI QSM software 
for implementation on their workstations. However, lesions close to the bone-tissue boundary 
may be left out of the automated selection of brain tissue, and the images would need to 
undergo careful quality assurance before being available for radiologists to read. 
 
In summary, our major findings were that DECT and QSM improved on the current clinical 
SECT threshold of 100 HU for differentiating between hemorrhagic and calcific lesions in a 
prospective clinical trial. In the future, we would like to pursue an additional clinical trial of 
patients with acute hemorrhage in an emergent setting. 
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7 Appendix 1 
Contraindications to MR Imaging 
Subjects and employees must report the presence of the following devices or conditions because 
they may be contraindications to MR, as reported in Appendix II of the American College of 
Radiology Guidance Document on MR Safe Practices (249): 
 
 Heart pacemaker or defibrillator 
 Neuro- or bio-stimulator 
 Cochlear implants 
 Cerebral aneurysm clips 
 Intravascular coils/filter/stents 
 Any metal in the eyes 
 Any ocular implant 
 Artificial heart valve 
 Surgical clips or staples 
 Implanted drug pump 
 Joint replacements 
 Limb prosthesis 
 Body piercing 
 Hearing aids 
 Internal electrodes/wires 
 Implants held by magnets 
 Bullet fragments/shrapnel 
 Existing catheters/ports 
 Eyelid spring 
 Tissue expander 
 Penile implant 
 Intrauterine contraceptive device 
 Rods/screws/plates 
 Any other implanted device 
 Medication patch 
 Tattoos 
 Halo vest 
 Spinal fixation device or spinal fusion 
procedure 
 Surgical mesh 
 Brachytherapy radioactive seeds
Additionally, all metallic objects must be removed from the subject’s person before their 
entering the MRI suite. Items specifically indicated by the American College of Radiology 
(249) include, but are not limited to: 
 
 
 Hearing aids 
 Pagers 
 Cell phones 
 Keys 
 Hair pins/Barrettes 
 Watches 
 Safety pins 
 Paper clips 
 Metallic money clips 
 Credit cards or any card with a 
magnetic strip 
 Coins 
 Pens 
 Pocket knives 
 Nail clippers 
 Steel-toed shoes 
 Tools 
 Dentures or false teeth 
 Eyeglasses 
 Clothing with metal fasteners or 
zippers 
 Jewelry, including body piercings 
 Any other loose, metallic items 
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8 Appendix 2 
Clinical Trial Screening Procedure and Software 
 
 
Figure 8.1: Clinical trial screening software example. 
The screening software, developed using a combination of Python, Javascript, and Standard 
Query Language (SQL), was a web-based application that pulled all T2*-weighted GRE MRI of 
the head from the Picture Archiving and Communication System (PACS). The daily screening 
was performed in which study personnel cycled through all of the series for a given day to 
identify foci of susceptibility with at least one axis longer than 1.0 cm, such as the two lesions 
shown in the patient image in Figure 8.1. The numeric references in the figure above represent 
the following: 
1. Patient Image 
Patient datasets are displayed in Area 1 (Figure 1). The white box in the upper left-hand 
corner of the image represents an area of 1cm x 1cm for reference. Users may scroll 
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through images by hovering the mouse over this image and using the up/down arrow 
keys or the scroll wheel on the mouse. 
2. Patient Information 
Relevant patient information is displayed in Area 2 (Figure 1). These include the MRN, 
Patient Name, Dataset number (out of total acquired that day), Series Description, and 
Image Number within the series. 
3. Image Selection and Commenting 
Images of interest may be “marked” for later review by clicking the “Mark Image” button 
in Area 3 (Figure 1). A comment may be entered before imaging marking by entering 
text into the empty box left of the “Mark Image” button. Patients may be selected as 
potential study recruits by clicking “Recruit Patient.”  
4. Cycle Button and Cycle Speed 
Users may cycle through the patient series by clicking “Cycle” (Area 4, Figure 1). Cycle 
speed may be adjusted in the box to the left. Alternatively, users may hover the mouse 
over the patient image and press “CTRL” on the keyboard to start and stop cycling. 
5. Marked Image Table 
Marked images appear along with patient information in Area 5 (Figure 2) along with any 
user comments and the MDA Username of the user that marked the image. 
6. Potential Recruit Table 
Patients that are eligible to be recruited to the study will be collected in Area 6 (Figure 2). 
7. Patient Image Buttons 
Clicking on these images (Area 7, Figure 2), will automatically open the image in the 
main image viewer. 
8. Open Study Button 
Opens a dialog box that allows the user to open a specific patient image series (Area 8, 
Figure 2). 
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9. Copy MRN Button 
Automatically copies the patient MRN for entry into Epic or iSite. A dialog box will appear 
to confirm that the data was copied successfully. 
10. Date Selection 
Clicking on the date (Area 10, Figure 2) brings up a calendar that allows the user to look 
at prior screening days. Click submit to go to images from that date. 
11. Table Controls 
The buttons located in Area 11 (Figure 2) control various table functions. “Refresh” 
reloads the tables. “Open Table In New Window” opens both tables in a full screen view 
with the recruiting table at the top. “Prelim Screening Complete” sends an e-mail to Dr. 
Schellingerhout noting that screening has been completed and is ready for review. 
“Send All Recruiting Emails” sends an e-mail to study staff, including the research 
nurses, containing the recruiting table and links to individual patient data pages. 
Lesions were marked when they were greater than 1.0 cm in length unless they represented 
one of the following known imaging artifacts or lesion types: 
1. Sinuses 
 
Figure 8.2: Dark lesion appearing in the right hemisphere (left, arrow). The next image in 
the series (middle) shows that both sides are symmetric. An example of the sagittal 
anatomy on T1-weighted imaging (https://www.imaios.com/en/e-Anatomy/Head-and-
Neck/Brain-MRI-3D) with the level of the "lesions" shown 
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2. Dura Mater Calcifications 
 
Figure 8.3: A calcification in the dura mater inside the skull (A) and separating the cerebral 
hemispheres (falx cerebri, B). These known calcifications can appear as dark lines along 
part or all of the falx cerebri. 
3. Basal Ganglia Mineralization 
 
Figure 8.4: Iron deposition in the putamen (left, arrows) and globus pallidus (right, arrows) 
in the basal ganglia. 
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4. Pineal Gland Calcification 
 
Figure 8.5: Pineal gland calcification located centrally in the image.  
5. Choroid Plexus Calcifications 
 
Figure 8.6: Choroid Plexus (arrows) mineralization. Usually found on the same slice or near 
the z-location of the pineal gland. 
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6. Dentate Nuclei 
 
Figure 8.7: Iron deposition found in the Dentate Nuclei (arrows) in the cerebellum. This can 
appear darker, similar to the basal ganglia examples. 
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